Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Sulfide SCHEMBL29272235 | 0.97 | CA1 (0.30) | CA1CA2CA7CA13 | |
| SCHEMBL3293217 | 0.79 | — | — | |
| Valine SCHEMBL6814434 | 0.76 | SLC7A5 (0.48) | — | |
| SCHEMBL8864066 | 0.74 | CA1 (0.33) | CA1CA2CA7CA13 | |
| SCHEMBL2261463 | 0.74 | CA2 (0.40) | CA1CA2 | |
| Ammonia Solution, Strong SCHEMBL28313868 | 0.72 | CA2 (0.39) | CA1CA2 | |
| SCHEMBL776607 | 0.70 | CA1 (0.30) | CA1CA2CA7CA13 | |
| SCHEMBL5079121 | 0.69 | — | — | |
| SCHEMBL15791696 | 0.69 | — | — | |
| SCHEMBL2159913 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1397 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3221284-A2 | 13-CIS-RAMBA RETINAMIDES THAT DEGRADE MNKS FOR TREATING CANCER | University of Maryland, Baltimore (US) | 2017-09-27 | — | — | EP | claimed |
| WO-2016081589-A2 | 13-CIS-RAMBA RETINAMIDES THAT DEGRADE MNKS FOR TREATING CANCER | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2016-05-26 | — | — | WO | claimed |
| WO-2014109712-A1 | PALLADIUM-CATALYZED ASYMMETRIC (HETERO)ARYLATION AND VINYLATION OF KETONE ENOLATES TO PRODUCE TERTIARY STEREOCENTERS AT ALPHA(α)-POSITION | NANAYNG TECHNOLOGICAL UNIVERSITY (SG) | 2014-07-17 | — | — | WO | claimed |
| WO-2011032034-A2 | NUCLEOBASE-FUNCTIONALIZED CONFORMATIONALLY RESTRICTED NUCLEOTIDES AND OLIGONUCLEOTIDES FOR TARGETING NUCLEIC ACIDS | UNIVERSITY OF IDAHO (US) | 2011-03-17 | — | — | WO | claimed |
| JP-2004505895-A | — | — | 2004-02-26 | — | — | JP | claimed |
| EP-1294660-A2 | METHOD FOR COUPLING ORGANIC COMPOUNDS | MERCK PATENT GmbH (DE) | 2003-03-26 | — | — | EP | claimed |
| US-6482851-B1 | Synthesis of dysidiolide and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2002-11-19 | — | — | US | claimed |
| US-20020165411-A1 | Sterically hindered phosphine ligands and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-11-07 | — | — | US | claimed |
| WO-2002048160-A1 | STERICALLY HINDERED PHOSPHINE LIGANDS AND USES THEREOF | YALE UNIVERSITY (US) | 2002-06-20 | — | — | WO | claimed |
| WO-2002000577-A2 | METHOD FOR COUPLING ORGANIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2002-01-03 | — | — | WO | claimed |
| WO-1999040079-A1 | SYNTHESIS OF DYSIDIOLIDE AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1999-08-12 | — | — | WO | claimed |
| US-5932743-A | Methods for the solid phase synthesis of substituted indole compounds | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-08-03 | — | — | US | claimed |
| WO-1999009007-A1 | SOLID PHASE SYNTHESIS OF 2,3-DISUBSTITUTED INDOLE COMPOUNDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-02-25 | — | — | WO | claimed |
| EP-0514942-B1 | Novel benzopyran derivatives and processes for the preparation thereof | KOREA RES INST CHEM TECH (KR) | 1997-03-05 | — | — | EP | claimed |
| EP-0660835-A4 | PROCESS FOR PREPARING CERTAIN PYRROLO 3,4- -I(B))QUINOLINES, CERTAIN 1H-PYRANO 3',4':6,7)INDOLIZINO 1,2--I(B))QUINOLIN-3,14(4H,12H)-DIONES, AND CERTAIN 8-METHYL-7-(OXOPROPYL)-INDOLIZINO 1,2--I(B))QUINOLIN-9(11H)-ONES. | — | 1995-08-16 | — | — | EP | claimed |
| EP-0660835-A1 | PROCESS FOR PREPARING CERTAIN PYRROLO 3,4- $i(b)]QUINOLINES, CERTAIN 1H-PYRANO 3',4':6,7]INDOLIZINO 1,2-$i(b)]QUINOLIN-3,14(4H,12H)-DIONES, AND CERTAIN 8-METHYL-7-(OXOPROPYL)-INDOLIZINO 1,2-$i(b)]QUINOLIN-9(11H)-ONES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-07-05 | — | — | EP | claimed |
| CN-1096297-A | The method of synthetic camptothecine and Mai Pi star and their analogue and allied compound | SMITHKLINE BEECHAM CORP (US) | 1994-12-14 | — | — | CN | claimed |
| WO-1994005672-A1 | PROCESS FOR PREPARING CERTAIN PYRROLO[3,4- b]QUINOLINES, CERTAIN 1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLIN-3,14(4H,12H)-DIONES, AND CERTAIN 8-METHYL-7-(OXOPROPYL)-INDOLIZINO[1,2-b]QUINOLIN-9(11H)-ONES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-03-17 | — | — | WO | claimed |
| EP-0514942-A1 | Novel benzopyran derivatives and processes for the preparation thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1992-11-25 | — | — | EP | claimed |
| EP-3433239-B1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12617745-B2 | Curcusone diterpenoids and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4729508-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | Arcus Biosciences, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12528776-B2 | Composition and method for treating dermatological disorders using retinamides | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4652171-A1 | TOTAL SYNTHESES OF PORTIMINE A AND ANALOGUES THEREOF AS SMALL MOLECULE MODULATORS OF NMD3 | The Scripps Research Institute (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-3221284-B1 | 13-CIS-RAMBA RETINAMIDES THAT DEGRADE MNKS FOR TREATING CANCER | UNIV MARYLAND (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250270252-A1 | CYCLIN-DEPENDENT KINASE DEGRADERS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250263398-A1 | PROCESS | ASSEMBLY BIOSCIENCES, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250250244-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H LUNDBECK AS (DK) | 2025-08-07 | — | — | US | disclosed |
| US-20250223277-A1 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS PHARMA AG (CH) | 2025-07-10 | — | — | US | disclosed |
| US-12351924-B2 | Electroreductive cross coupling | OHIO STATE INNOVATION FOUNDATION (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250214930-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-12325725-B2 | Cyclin-dependent kinase degraders and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| CN-120117948-A | Synthesis method of alpha, beta-unsaturated cyclohexene formaldehyde | 西安瑞联新材料股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| WO-2025104209-A1 | ANTI-OBESITY AND ANTI-DIABETIC ACTIVITY OF BROMINATED DITERPENES FROM RED ALGAE OF THE GENUS LAURENCIA AND APPLICATIONS THEREOF | NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS (GR) | 2025-05-22 | — | — | WO | disclosed |
| EP-4556003-A1 | ANTI-OBESITY AND ANTI-DIABETIC ACTIVITY OF BROMINATED DITERPENES FROM RED ALGAE OF THE GENUS LAURENCIA AND APPLICATIONS THEREOF | National and Kapodistrian University of Athens (GR) | 2025-05-21 | — | — | EP | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250154177-A1 | PYRROLOBENZODIAZEPINE INTERMEDIATES AND USES THEREOF | SIGMA-ALDRICH CO. LLC | 2025-05-15 | — | — | US | disclosed |
| US-20250115572-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS PHARMA AG (CH) | 2025-04-10 | — | — | US | disclosed |
| EP-3752517-B1 | CYCLIN-DEPENDENT KINASE DEGRADERS AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-115108905-B | Method for producing (Z) -trifluoromethaneenol ester by copper-catalyzed regioselective olefination and trifluoromethylation of carboxylic acid | 湖南大学 | 2025-04-08 | — | — | CN | disclosed |
| CN-115108905-B | Method for producing (Z) -trifluoromethaneenol ester by copper-catalyzed regioselective olefination and trifluoromethylation of carboxylic acid | 湖南大学 | 2025-04-08 | — | — | CN | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-119562955-A | Pyrrolo-benzodiazepines intermediate and use thereof | 西格马-奥尔德里奇有限责任公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12195447-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| CN-119181853-A | Sodium ion battery electrolyte additive, composition thereof, electrolyte and sodium ion battery containing electrolyte | 苏州祺添新材料股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| CN-119137099-A | Complement factor B inhibitors and uses thereof | 诺华股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-119118872-A | Tetrahydronaphthalene and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-4469157-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| EP-3752518-B1 | CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2024-12-04 | — | — | EP | disclosed |
| US-12116355-B2 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | H. LUNDBECK A/S (DK) | 2024-10-15 | — | — | US | disclosed |
| US-12103907-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | ARCUS BIOSCIENCES, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| CN-118696035-A | Spiropiperidyl derivatives as complement factor B inhibitors and their use | 诺华股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| CN-115298165-B | Tetrahydronaphthalene and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2024-09-17 | — | — | CN | disclosed |
| EP-4419519-A1 | PROCESS | Assembly Biosciences, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240254079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2024-08-01 | — | — | US | disclosed |
| US-12048710-B2 | Compositions and methods for modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240246988-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-07-25 | — | — | US | disclosed |
| WO-2024155680-A1 | TOTAL SYNTHESES OF PORTIMINE A AND ANALOGUES THEREOF AS SMALL MOLECULE MODULATORS OF NMD3 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-07-25 | — | — | WO | disclosed |
| US-12037327-B2 | Compounds and methods targeting GPER for treatment of diseases associated with calcium | SAINT LOUIS UNIVERSITY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-12018001-B2 | Pyrimidine cyclohexenyl glucocorticoid receptor modulators | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-06-25 | — | — | US | disclosed |
| CN-118215659-A | Process for producing a solid-state image sensor | 组装生物科学股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-11999727-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| WO-2024112123-A1 | NOVEL COMPOUND AS SELECTIVE ESTROGEN RECEPTOR MODULATOR | 재단법인 대구경북첨단의료산업진흥재단 | 2024-05-30 | — | — | WO | disclosed |
| US-20240165259-A1 | BIOORTHOGONAL REACTION SUITABLE FOR CLICK/UNCLICK APPLICATIONS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| EP-3802499-B1 | PYRIMIDINE CYCLOHEXENYL GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11932601-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112236416-B | Pyrimidine cyclohexenyl glucocorticoid receptor modulators | 科赛普特治疗公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-4320073-A1 | BIOORTHOGONAL REACTION SUITABLE FOR CLICK/UNCLICK APPLICATIONS | Dana-Farber Cancer Institute, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-4310082-A2 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | Arcus Biosciences, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-112300172-B | Bruton tyrosine kinase inhibitors | 比奥根MA公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-117337267-A | Bioorthogonal reactions suitable for click/click cancellation applications | 达纳－法伯癌症研究所公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230406803-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Kinesid Therapeutics, Inc (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230365620-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| CN-112204020-B | Dioxetane compounds and their use for detecting microorganisms | 尼米斯技术公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11787762-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | ARCUS BIOSCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
| CN-116768859-A | Azolopyrimidines for the treatment of cancer related disorders | 艾库斯生物科学有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023173096-A1 | PYRROLOBENZODIAZEPINE INTERMEDIATES AND USES THEREOF | SIGMA-ALDRICH CO. LLC (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-3570844-B1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116669713-A | CURCUSONE diterpene and application thereof | 普渡研究基金会 | 2023-08-29 | — | — | CN | disclosed |
| US-20230265480-A1 | METHOD FOR DETECTION OF MICROORGANISMS | NEMIS TECH AG (CH) | 2023-08-24 | — | — | US | disclosed |
| CN-110997654-B | Indole derivatives and uses thereof | 诺华股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230250042-A1 | CURCUSONE DITERPENOIDS AND USES THEREOF | UNIVERSITY OF FLORIDA BOARD OF TRUSTEES | 2023-08-10 | — | — | US | disclosed |
| US-20230250539-A1 | ELECTROREDUCTIVE CROSS COUPLING | OHIO STATE INNOVATION FOUNDATION | 2023-08-10 | — | — | US | disclosed |
| EP-4221697-A1 | CURCUSONE DITERPENOIDS AND USES THEREOF | Purdue Research Foundation (US) | 2023-08-09 | — | — | EP | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2023139534-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| EP-4215512-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H. Lundbeck A/S (DK) | 2023-07-26 | — | — | EP | disclosed |
| CN-112262139-B | Aminopyrrolotriazines as kinase inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230203081-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230183186-A1 | PYRIMIDINE CYCLOHEXENYL GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INCORPORATED | 2023-06-15 | — | — | US | disclosed |
| EP-3071541-B1 | SUBSTITUTED (4'-HYDROXYPHENYL)CYCLOALKANE COMPOUNDS AND USES THEREOF AS SELECTIVE AGONISTS OF THE ESTROGEN RECEPTOR BETA ISOFORM | UNIV MARQUETTE (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11649475-B2 | Dioxetane compounds and their use for the detection of microorganisms | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2023-05-16 | — | — | US | disclosed |
| US-11649212-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-16 | — | — | US | disclosed |
| CN-110214012-B | Azolopyrimidines for the treatment of cancer related disorders | 艾库斯生物科学有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023067518-A1 | PROCESS | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-11634378-B2 | Compounds and methods targeting GPER in calcium disorders | SAINT LOUIS UNIVERSITY (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230114498-A1 | COMPOSITION AND METHOD FOR TREATING DERMATOLOGICAL DISORDERS USING RETINAMIDES | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-04-13 | — | — | US | disclosed |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-04 | — | — | US | disclosed |
| US-11608347-B2 | Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20230046457-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN MA INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230021476-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4121409-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | Arcus Biosciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3508468-B1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H LUNDBECK AS (DK) | 2023-01-18 | — | — | EP | disclosed |
| US-11542238-B2 | Pyrimidine cyclohexenyl glucocorticoid receptor modulators | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-01-03 | — | — | US | disclosed |
| CN-115515934-A | NAMPT modulators | 赛特凯恩蒂克公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-4100393-A1 | NAMPT MODULATORS | Cytokinetics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-11505534-B2 | Highly diastereoselective construction of the 4,5-spirocycle via palladium-catalyzed intramolecular alkenylation | THE UNIVERSITY OF CHICAGO (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2022-11-10 | — | — | US | disclosed |
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| CN-115298165-A | Tetralin and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2022-11-04 | — | — | CN | disclosed |
| EP-3658546-B1 | INDOLE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-10-26 | — | — | EP | disclosed |
| EP-4076668-A1 | COMPOSITION AND METHOD FOR TREATING DERMATOLOGICAL DISORDERS USING RETINAMIDES | University of Maryland, Baltimore (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022216616-A1 | BIOORTHOGONAL REACTION SUITABLE FOR CLICK/UNCLICK APPLICATIONS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| CN-115087487-A | Compositions and methods for treating skin disorders using tretinoin | 马里兰大学巴尔的摩分校 | 2022-09-20 | — | — | CN | disclosed |
| CN-115066418-A | Carboxy derivatives with anti-inflammatory properties | 西特瑞治疗有限公司 | 2022-09-16 | — | — | CN | disclosed |
| US-20220274926-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2022-09-01 | — | — | US | disclosed |
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-08-30 | — | — | US | disclosed |
| EP-4045477-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Ambys Medicines, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-11407712-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α | ARCUS BIOSCIENCES, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220202837-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-30 | — | — | US | disclosed |
| US-20220177508-A1 | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| EP-4008328-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| CN-110049985-B | Heterocyclic sulfones as ROR gamma modulators | 百时美施贵宝公司 | 2022-05-31 | — | — | CN | disclosed |
| US-11337970-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220144808-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2022-05-12 | — | — | US | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220119362-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2022-04-21 | — | — | US | disclosed |
| CN-107406414-B | (piperidin-3-yl) (naphthalen-2-yl) methanone derivatives as inhibitors of histone demethylase KDM2B for the treatment of cancer | 基因泰克公司 | 2022-04-19 | — | — | CN | disclosed |
| WO-2022072266-A1 | CURCUSONE DITERPENOIDS AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2022-04-07 | — | — | WO | disclosed |
| US-11283107-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-03-22 | — | — | US | disclosed |
| US-11278554-B2 | Compositions and methods for modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-22 | — | — | US | disclosed |
| US-11253525-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
| US-11242319-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| WO-2022026892-A1 | PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS | TANGO THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2021236911-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-25 | — | — | WO | disclosed |
| US-11179400-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| CN-113646319-A | C11-ring-substituted 13-membered macrolides and their use | 齐卡尼治疗股份有限公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-108391422-B | Pyrrolobenzodiazepine antibody-drug conjugates and methods of use | 豪夫迈·罗氏有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20210317079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| EP-3177282-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3883945-A1 | C11-CYCLIC SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | Zikani Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| WO-2021188769-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20210246127-A1 | COMPOUNDS AND METHODS TARGETING GPER FOR TREATMENT OF DISEASES ASSOCIATED WITH CALCIUM | ST. LOUIS UNIVERSITY (US) | 2021-08-12 | — | — | US | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20210238148-A1 | PYRIMIDINE CYCLOHEXENYL GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INCORPORATED | 2021-08-05 | — | — | US | disclosed |
| EP-3854394-A1 | IMMUNOREGULATORY AGENTS | Flexus Biosciences, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| US-11072597-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. | 2021-07-27 | — | — | US | disclosed |
| US-20210214766-A1 | DIOXETANE COMPOUNDS AND THEIR USE FOR THE DETECTION OF MICROORGANISMS | NEMIS TECHNOLOGIES AG (CH) | 2021-07-15 | — | — | US | disclosed |
| US-20210206723-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-07-08 | — | — | US | disclosed |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2021-07-06 | — | — | US | disclosed |
| CN-107428741-B | Cyclic compounds substituted by condensed ring systems | 巴斯夫欧洲公司 | 2021-06-25 | — | — | CN | disclosed |
| WO-2021127438-A1 | COMPOSITION AND METHOD FOR TREATING DERMATOLOGICAL DISORDERS USING RETINAMIDES | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20210186963-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2021-06-17 | — | — | US | disclosed |
| CN-112812147-A | Synthetic method of abiraterone acetate and intermediate thereof | 江苏佳尔科药业集团股份有限公司 | 2021-05-18 | — | — | CN | disclosed |
| EP-3300736-B1 | COMPOSITION COMPRISING ANTIBIOTIC COMPOUND AND AN HETEROCYCLIC COMPOUND AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2021-05-05 | — | — | EP | disclosed |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| WO-2021076938-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Ambys Medicines, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-10980806-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-04-20 | — | — | US | disclosed |
| CN-107427499-B | Immunomodulator | 弗莱塞斯生物科学公司 | 2021-04-16 | — | — | CN | disclosed |
| EP-3802511-A1 | DIOXETANE COMPOUNDS AND THEIR USE FOR THE DETECTION OF MICROORGANISMS | Nemis Technologies AG (CH) | 2021-04-14 | — | — | EP | disclosed |
| EP-3802499-A1 | PYRIMIDINE CYCLOHEXENYL GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics Incorporated (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20210101880-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2021-04-08 | — | — | US | disclosed |
| US-20210087134-A1 | COMPOUNDS AND METHODS TARGETING GPER IN CALCIUM DISORDERS | SAINT LOUIS UNIVERSITY (US) | 2021-03-25 | — | — | US | disclosed |
| US-20210054020-A1 | CYCLIN-DEPENDENT KINASE DEGRADERS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-25 | — | — | US | disclosed |
| CN-112279808-A | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2021-01-29 | — | — | CN | disclosed |
| US-20210024546-A1 | OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-01-28 | — | — | US | disclosed |
| CN-112250627-A | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2021-01-22 | — | — | CN | disclosed |
| CN-112262139-A | Aminopyrrolotriazines as kinase inhibitors | 百时美施贵宝公司 | 2021-01-22 | — | — | CN | disclosed |
| CN-112236416-A | Pyrimidine cyclohexenyl glucocorticoid receptor modulators | 科赛普特治疗公司 | 2021-01-15 | — | — | CN | disclosed |
| EP-3752518-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3752517-A1 | CYCLIN-DEPENDENT KINASE DEGRADERS AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3215153-B1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3368539-B1 | SUBSTITUTED INDAZOLE COMPOUNDS AS ROR GAMMA T INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3743430-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200369715-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| EP-3737680-A1 | OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2020-11-18 | — | — | EP | disclosed |
| CN-107690281-B | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2020-11-17 | — | — | CN | disclosed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
| EP-3355935-B1 | PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2020-10-21 | — | — | EP | disclosed |
| US-20200323872-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2020-10-15 | — | — | US | disclosed |
| WO-2020210246-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC, (US) | 2020-10-15 | — | — | WO | disclosed |
| US-10793525-B2 | 13-cis-RAMBA retinamides that degrade MNKs for treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-10-06 | — | — | US | disclosed |
| CN-107580595-B | Heterocyclic compounds and their use in the prevention or treatment of bacterial infections | 拜欧蒂姆公司 | 2020-09-18 | — | — | CN | disclosed |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| CN-111566105-A | Octahydropyrido [1, 2-alpha ] pyrazines as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2020-08-21 | — | — | CN | disclosed |
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
| EP-3368516-B1 | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-3226688-B1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20200199038-A1 | DICARBOXYLIC FATTY ACID DIMERS, AND DERIVATIVES THEREOF, AS STANDARDS FOR QUANTIFYING LEVELS IN BIOSPECIMENS | MED-LIFE DISCOVERIES LP (CA) | 2020-06-25 | — | — | US | disclosed |
| US-10689369-B2 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2020-06-23 | — | — | US | disclosed |
| EP-3658546-A1 | INDOLE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2020-06-03 | — | — | EP | disclosed |
| US-10662171-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3226690-B1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME (US) | 2020-05-20 | — | — | EP | disclosed |
| US-10654828-B2 | Indole derivatives and uses thereof | NOVARTIS AG (CH) | 2020-05-19 | — | — | US | disclosed |
| CN-111182967-A | Transition metal catalyzed aryl/vinyl halide cyanation process | 科勒研究有限公司 | 2020-05-19 | — | — | CN | disclosed |
| EP-3317271-B1 | INHIBITORS OF EZH2 (ENHANCER OF ZESTE HOMOLOG 2) | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-05-13 | — | — | EP | disclosed |
| US-10639373-B2 | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | GENENTECH, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| CN-105960395-B | Cyclopentene and cyclopentadiene compounds for controlling invertebrate pests | 巴斯夫欧洲公司 | 2020-05-01 | — | — | CN | disclosed |
| US-10632196-B2 | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | GENENTECH, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3638683-A1 | DICARBOXYLIC FATTY ACID DIMERS, AND DERIVATIVES THEREOF, AS STANDARDS FOR QUANTIFYING LEVELS IN BIOSPECIMENS | Med-Life Discoveries LP (CA) | 2020-04-22 | — | — | EP | disclosed |
| CN-110997654-A | Indole derivatives and uses thereof | 诺华股份有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20200079749-A1 | HIGHLY DIASTEREOSELECTIVE CONSTRUCTION OF THE 4,5-SPIROCYCLE VIA PALLADIUM-CATALYZED INTRAMOLECULAR ALKENYLATION | THE UNIVERSITY OF CHICAGO | 2020-03-12 | — | — | US | disclosed |
| EP-3621141-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-10570077-B2 | Substituted (4'-hydroxyphenyl)cyclohexane compounds and uses thereof as selective agonists of the estrogen receptor beta isoform | MARQUETTE UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-10565015-B2 | Spiroketal-based C2-symmetric scaffold for asymmetric catalysis | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-02-18 | — | — | US | disclosed |
| US-20200046742-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-13 | — | — | US | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
| CN-110741007-A | Dicarboxylic acid fatty acid dimers and derivatives thereof as quantitative level standards in biological samples | 医学生命探索有限公司 | 2020-01-31 | — | — | CN | disclosed |
| US-10544110-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-01-28 | — | — | US | disclosed |
| CN-110650735-A | Highly diastereoselective structures of 4, 5-spirocycles by palladium-catalyzed intramolecular alkenylation | 芝加哥大学 | 2020-01-03 | — | — | CN | disclosed |
| US-20190352262-A1 | New Pleuromutilin Antibiotic Compounds, Compositions and Methods of Use and Synthesis | UNIV YALE (US) | 2019-11-21 | — | — | US | disclosed |
| US-10472392-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10463391-B2 | Magnetic ferrocenyl-functionalized nanoparticle | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-11-05 | — | — | US | disclosed |
| US-10442819-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | MERCK SHARP & DOHME CORP. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10434111-B2 | Compositions and methods for modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-08 | — | — | US | disclosed |
| CN-105530932-B | Primary formamide as BTK inhibitor | 艾伯维公司 | 2019-09-27 | — | — | CN | disclosed |
| US-20190284135-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2019-09-19 | — | — | US | disclosed |
| US-20190276438-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2019-09-12 | — | — | US | disclosed |
| US-10407383-B2 | Cyclopentene and cyclopentadiene compounds for controlling invertebrate pests | BASF SE (DE) | 2019-09-10 | — | — | US | disclosed |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-05 | — | — | US | disclosed |
| EP-3292125-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2019-09-04 | — | — | EP | disclosed |
| US-10399962-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10392360-B2 | Synthetic route to anhydroryanodol, ryanodol and structural analogues | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-08-27 | — | — | US | disclosed |
| WO-2019160890-A1 | CYCLIN-DEPENDENT KINASE DEGRADERS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| WO-2019160889-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| US-10377724-B2 | Aryl halide cross-coupling method and product made therefrom | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-08-13 | — | — | US | disclosed |
| US-10377723-B2 | Solid-supported catalyst for cross-coupling | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-08-13 | — | — | US | disclosed |
| US-10370397-B2 | Phosphine substituted ferrocenyl complex | Kind Fahd University of Petroleum and Minerals (SA) | 2019-08-06 | — | — | US | disclosed |
| WO-2019147782-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | WO | disclosed |
| US-20190229372-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-07-25 | — | — | US | disclosed |
| EP-3099701-B1 | PROCEDURE FOR THE PREPARATION OF ABIRATERONE ACETATE AND INTERMEDIATES THEREOF | OLON SPA (IT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2019134985-A1 | OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-07-11 | — | — | WO | disclosed |
| US-10344000-B2 | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2019-07-09 | — | — | US | disclosed |
| EP-3242872-B1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2019-07-03 | — | — | EP | disclosed |
| US-10333172-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| US-10322995-B2 | Substituted cyano cycloalkyl penta-2,4-dienes, cyano cycloalkyl pent-2-en-4-ynes, cyano heterocyclyl penta-2,4-dienes and cyano heterocyclyl pent-2-en-4-ynes as active substances against abiotic plant stress | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-06-18 | — | — | US | disclosed |
| CN-109843293-A | The inhibitor and its application method of indole amine 2,3-dioxygenase | 百时美施贵宝公司 | 2019-06-04 | — | — | CN | disclosed |
| US-20190161458-A1 | ARYL HALIDE CROSS-COUPLING METHOD AND PRODUCT MADE THEREFROM | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-05-30 | — | — | US | disclosed |
| US-20190161457-A1 | SOLID-SUPPORTED CATALYST FOR CROSS-COUPLING | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-05-30 | — | — | US | disclosed |
| EP-3483167-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2019-05-15 | — | — | EP | disclosed |
| US-10290901-B2 | — | — | 2019-05-14 | — | — | US | disclosed |
| US-10287272-B2 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| EP-2970335-B1 | MACROCYCLIC AND BICYCLIC INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10280149-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-10280147-B2 | Solid-supported palladium (II) complex as a heterogeneous catalyst for cross coupling reactions and methods thereof | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-05-07 | — | — | US | disclosed |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-2216312-B1 | PROCESS FOR PRODUCING ORGANIC COMPOUND | M TECHNIQUE CO LTD (JP) | 2019-05-01 | — | — | EP | disclosed |
| CN-109651342-A | The inhibitor of hepatitis c viral replication | 默沙东公司 | 2019-04-19 | — | — | CN | disclosed |
| WO-2019074822-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-18 | — | — | WO | disclosed |
| US-10258624-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-04-16 | — | — | US | disclosed |
| EP-3102563-B1 | CYCLOPENTENE AND CYCLOPENTADIENE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | BASF SE (DE) | 2019-04-10 | — | — | EP | disclosed |
| US-10246486-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-RE47334-E1 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20190092729-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2019-03-28 | — | — | US | disclosed |
| US-20190084995-A1 | Spiroketal-Based C2-Symmetric Scaffold For Asymmetric Catalysis | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-03-21 | — | — | US | disclosed |
| CN-107417582-B | A kind of preparation method of E- alkenyl sulfone compound | 曲阜师范大学 | 2019-03-19 | — | — | CN | disclosed |
| US-20190055219-A1 | INDOLE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2019-02-21 | — | — | US | disclosed |
| US-10202400-B2 | Cortistatin analogues and syntheses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-02-12 | — | — | US | disclosed |
| WO-2019021059-A1 | INDOLE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2019-01-31 | — | — | WO | disclosed |
| US-20190031697-A1 | PHOSPHINE SUBSTITUTED FERROCENYL COMPLEX | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-01-31 | — | — | US | disclosed |
| US-20190029718-A1 | MAGNETIC FERROCENYL-FUNCTIONALIZED NANOPARTICLE | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-01-31 | — | — | US | disclosed |
| EP-3433239-A1 | SMALL MOLECULE INHIBITOR OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | University of Pittsburgh- Of the Commonwealth System of Higher Education (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20190022093-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-01-24 | — | — | US | disclosed |
| US-10183943-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | MUTABILIS (FR) | 2019-01-22 | — | — | US | disclosed |
| US-20190002472-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190002411-A1 | 13-Cis-RAMBA RETINAMIDES THAT DEGRADE MNKs FOR TREATING CANCER | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2019-01-03 | — | — | US | disclosed |
| EP-2991980-B1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-01-02 | — | — | EP | disclosed |
| WO-2018227306-A1 | DICARBOXYLIC FATTY ACID DIMERS, AND DERIVATIVES THEREOF, AS STANDARDS FOR QUANTIFYING LEVELS IN BIOSPECIMENS | MED-LIFE DISCOVERIES LP (CA) | 2018-12-20 | — | — | WO | disclosed |
| US-10150109-B2 | Palladium(II)-silica supported catalyst | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-12-11 | — | — | US | disclosed |
| US-10150111-B2 | Method for catalytic synthesis of cinnamic acid with catalyst recycle | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-12-11 | — | — | US | disclosed |
| US-10150110-B2 | Method for making and using a solid-supported catalyst | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-12-11 | — | — | US | disclosed |
| WO-2018213442-A1 | HIGHLY DIASTEREOSELECTIVE CONSTRUCTION OF THE 4,5-SPIROCYCLE VIA PALLADIUM-CATALYZED INTRAMOLECULAR ALKENYLATION | THE UNIVERSITY OF CHICAGO (US) | 2018-11-22 | — | — | WO | disclosed |
| US-20180326409-A1 | METHOD FOR MAKING AND USING A SOLID-SUPPORTED CATALYST | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-11-15 | — | — | US | disclosed |
| US-20180326062-A1 | PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2018-11-15 | — | — | US | disclosed |
| US-20180326410-A1 | METHOD FOR CATALYTIC SYNTHESIS OF CINNAMIC ACID WITH CATALYST RECYCLE | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-11-15 | — | — | US | disclosed |
| US-10125159-B2 | Functionalized magnetic nanoparticle, a catalyst, a method for forming C—C bonds | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-11-13 | — | — | US | disclosed |
| US-20180312489-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2018-11-01 | — | — | US | disclosed |
| EP-3013337-B1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180305320-A1 | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2018-10-25 | — | — | US | disclosed |
| EP-3392253-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | Gilead Sciences, Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| CN-104662033-B | Macrocyclic Inhibitors of Flaviviridae Viruses | 吉利德科学公司 | 2018-10-23 | — | — | CN | disclosed |
| US-10106535-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-10106546-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| EP-3013848-B1 | PROCESS FOR THE PREPARATION OF ABIRATERONE AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN LTD (TW) | 2018-10-17 | — | — | EP | disclosed |
| US-20180282281-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2018-10-04 | — | — | US | disclosed |
| WO-2018183659-A1 | COMPOUNDS AND METHODS TARGETING GPER IN CALCIUM DISORDERS | SAINT LOUIS UNIVERSITY (US) | 2018-10-04 | — | — | WO | disclosed |
| US-10086000-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | MERCK SHARP & DOHME CORP. (US) | 2018-10-02 | — | — | US | disclosed |
| CN-103880862-B | The inhibitor of hepatitis c viral replication | 默沙东公司 | 2018-09-25 | — | — | CN | disclosed |
| EP-3368539-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-3368516-A1 | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2018-09-05 | — | — | EP | disclosed |
| US-10058613-B2 | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | GENENTECH, INC. (US) | 2018-08-28 | — | — | US | disclosed |
| US-10058856-B2 | Method for palladium-catalyzed cinammic acid formation | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-08-28 | — | — | US | disclosed |
| US-20180237403-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-08-23 | — | — | US | disclosed |
| CN-108391422-A | Pyrrolobenzodiazepine antibody-drug conjugates and methods of use | 豪夫迈·罗氏有限公司 | 2018-08-10 | — | — | CN | disclosed |
| WO-2018144717-A1 | NEW PLEUROMUTILIN ANTIBIOTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND SYNTHESIS | YALE UNIVERSITY (US) | 2018-08-09 | — | — | WO | disclosed |
| EP-3355935-A1 | PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2018-08-08 | — | — | EP | disclosed |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
| WO-2018136700-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-20180200705-A1 | METHOD FOR PALLADIUM-CATALYZED CINAMMIC ACID FORMATION | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-07-19 | — | — | US | disclosed |
| US-20180200706-A1 | PALLADIUM(II)-SILICA SUPPORTED CATALYST | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-07-19 | — | — | US | disclosed |
| US-10023563-B2 | Cyclic compounds substituted by a condensed ring system | BASF SE (DE) | 2018-07-17 | — | — | US | disclosed |
| EP-3169662-B1 | SUBSTITUTED VINYL- AND ALKINYL-CYANOCYCLOALKANOLS AND VINYL- AND ALKINYL-CYANOHETEROCYCLOALKANOLS AS AGENTS TO COMBAT ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2018-07-11 | — | — | EP | disclosed |
| US-20180185486-A1 | PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180162845-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-06-14 | — | — | US | disclosed |
| EP-3331533-A1 | SYNTHESIS AND BIOLOGICAL ACTIVITY OF 2-METHYLENE ANALOGS OF CALCITRIOL AND RELATED COMPOUNDS | Wisconsin Alumni Research Foundation (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-1904069-B1 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RES INC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9988377-B2 | Small molecule inducers of GDNF as potential new therapeutics for neuropsychiatric disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-06-05 | — | — | US | disclosed |
| EP-3317271-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2018-05-09 | — | — | EP | disclosed |
| WO-2018081047-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
| US-20180118706-A1 | Synthetic Route To Anhydroryanodol, Ryanodol And Structural Analogues | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2018-05-03 | — | — | US | disclosed |
| US-9956550-B2 | Solid-supported palladium(II) complex for catalyzing Mizoroki-Heck coupling reactions and a method thereof | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-05-01 | — | — | US | disclosed |
| CN-104583218-B | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 百时美施贵宝公司 | 2018-04-24 | — | — | CN | disclosed |
| US-20180099987-A1 | FUNCTIONALIZED MAGNETIC NANOPARTICLE, A CATALYST, A METHOD FOR FORMING C-C BONDS | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-04-12 | — | — | US | disclosed |
| WO-2018060484-A1 | COMPOSITION COMPRISING ANTIBIOTIC COMPOUND AND AN HETEROCYCLIC COMPOUND AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2018-04-05 | — | — | WO | disclosed |
| US-20180093985-A1 | Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections | MUTABILIS (FR) | 2018-04-05 | — | — | US | disclosed |
| EP-3300736-A1 | COMPOSITION COMPRISING ANTIBIOTIC COMPOUND AND AN HETEROCYCLIC COMPOUND AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | Mutabilis (FR) | 2018-04-04 | — | — | EP | disclosed |
| EP-3301094-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | Mutabilis (FR) | 2018-04-04 | — | — | EP | disclosed |
| CN-107849032-A | The inhibitor of ZESTE enhancers homologue 2 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-104703991-B | Macrocyclic Inhibitors of Flaviviridae Viruses | 吉利德科学公司 | 2018-03-23 | — | — | CN | disclosed |
| EP-3292125-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | Mutabilis (FR) | 2018-03-14 | — | — | EP | disclosed |
| US-20180065117-A1 | SOLID-SUPPORTED PALLADIUM(II) COMPLEX FOR CATALYZING MIZOROKI-HECK COUPLING REACTIONS AND A METHOD THEREOF | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-03-08 | — | — | US | disclosed |
| EP-2861601-B1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2018-02-07 | — | — | EP | disclosed |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| EP-2501669-B1 | ARYLATED CAMPHENES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2018-01-24 | — | — | EP | disclosed |
| US-9873716-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| CN-107580595-A | Heterocyclic compounds and their use in the prevention or treatment of bacterial infections | 拜欧蒂姆公司 | 2018-01-12 | — | — | CN | disclosed |
| US-9862696-B2 | Synthetic route to anhydroryanodol, ryanodol and structural analogues | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-01-09 | — | — | US | disclosed |
| CN-107522584-A | A kind of α trifluoromethyl ketones compound and preparation method thereof | 沈阳师范大学 | 2017-12-29 | — | — | CN | disclosed |
| US-20170369507-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170369479-A1 | CYCLIC COMPOUNDS SUBSTITUTED BY A CONDENSED RING SYSTEM | BASF SE (DE) | 2017-12-28 | — | — | US | disclosed |
| US-20170360800-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362220-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| CN-107427499-A | Immunomodulator | 弗莱塞斯生物科学公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-107417582-A | A kind of preparation method of E alkenyl sulfone compounds | 曲阜师范大学 | 2017-12-01 | — | — | CN | disclosed |
| CN-107406414-A | (piperidin-3-yl) (naphthalen-2-yl) methanone derivatives and related compounds as inhibitors of histone demethylase KDM2B for the treatment of cancer | 基因泰克公司 | 2017-11-28 | — | — | CN | disclosed |
| US-20170334891-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| EP-3242872-A1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170320886-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170313745-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2017-11-02 | — | — | US | disclosed |
| EP-3237395-A1 | CYCLIC COMPOUNDS SUBSTITUTED BY A CONDENSED RING SYSTEM | BASF SE (DE) | 2017-11-01 | — | — | EP | disclosed |
| US-20170305900-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2017-10-26 | — | — | US | disclosed |
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2859009-B1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9790212-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-20170291905-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-12 | — | — | US | disclosed |
| EP-3226689-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | Merck Sharp & Dohme Corp. (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-3226690-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | Merck Sharp & Dohme Corp. (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-3226688-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | Merck Sharp & Dohme Corp. (US) | 2017-10-11 | — | — | EP | disclosed |
| US-9782408-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170283434-A1 | NK1 ANTAGONISTS | OPKO HEALTH INC (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170275318-A1 | SOLID-SUPPORTED PALLADIUM (II) COMPLEX AS A HETEROGENEOUS CATALYST FOR CROSS COUPLING REACTIONS AND METHODS THEREOF | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2017-09-28 | — | — | US | disclosed |
| WO-2017165822-A1 | SMALL MOLECULE INHIBITOR OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-09-28 | — | — | WO | disclosed |
| EP-3221284-A2 | 13-CIS-RAMBA RETINAMIDES THAT DEGRADE MNKS FOR TREATING CANCER | University of Maryland, Baltimore (US) | 2017-09-27 | — | — | EP | disclosed |
| CN-107205970-A | Immunomodulator | 弗莱塞斯生物科学公司 | 2017-09-26 | — | — | CN | disclosed |
| US-20170267642-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-09-21 | — | — | US | disclosed |
| EP-3215153-A1 | IMMUNOREGULATORY AGENTS | Flexus Biosciences, Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-3215141-A2 | IMMUNOREGULATORY AGENTS | Flexus Biosciences, Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20170253546-A1 | SYNTHESIS AND BIOLOGICAL ACTIVITY OF 2-METHYLENE ANALOGS OF CALCITRIOL AND RELATED COMPOUNDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-09-07 | — | — | US | disclosed |
| EP-3212639-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-09-06 | — | — | EP | disclosed |
| CN-104781261-B | The macrocyclic hcv inhibitors of flaviviridae | 吉利德科学公司 | 2017-08-25 | — | — | CN | disclosed |
| EP-3203840-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9724332-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170217920-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-08-03 | — | — | US | disclosed |
| EP-2758377-B1 | CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20170210701-A1 | SUBSTITUTED CYANO CYCLOALKYL PENTA-2,4-DIENES, CYANO CYCLOALKYL PENT-2-EN-4-YNES, CYANO HETEROCYCLYL PENTA-2,4-DIENES AND CYANO HETEROCYCLYL PENT-2-EN-4-YNES AS ACTIVE SUBSTANCES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-07-27 | — | — | US | disclosed |
| US-9714255-B2 | Cortistatin analogues and syntheses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170197910-A1 | SUBSTITUTED VINYL AND ALKYNYL CYANOCYCLOALKANOLS AND VINYL AND ALKYNYL CYANOHETEROCYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-07-13 | — | — | US | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197973-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170190737-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20170190734-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | Selcia Ltd. (GB) | 2017-07-06 | — | — | US | disclosed |
| US-9688693-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688596-B2 | Synthesis and biological activity of 2-methylene analogs of calcitriol and related compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-06-27 | — | — | US | disclosed |
| WO-2017106649-A1 | SYNTHETIC ROUTE TO ANHYDRORYANODOL, RYANODOL, AND STRUCTURAL ANALOGUES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174648-A1 | Synthetic Route To Anhydroryanodol, Ryanodol And Structural Analogues | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2017-06-22 | — | — | US | disclosed |
| US-20170174624-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2017-06-22 | — | — | US | disclosed |
| EP-3177282-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-2758389-B1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-3172187-A1 | SUBSTITUTED CYANO CYCLOALKYL PENTA-2,4-DIENES, CYANO CYCLOALKYL PENT-2-EN-4-YNES, CYANO HETEROCYCLYL PENTA-2,4-DIENES AND CYANO HETEROCYCLYL PENT-2-EN-4-YNES AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | Bayer CropScience Aktiengesellschaft (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-3169662-A1 | SUBSTITUTED VINYL AND ALKYNYL CYANOCYCLOALKANOLS AND VINYL AND ALKYNYL CYANOHETEROCYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | Bayer CropScience Aktiengesellschaft (DE) | 2017-05-24 | — | — | EP | disclosed |
| US-9642889-B2 | Macrocyclic inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643972-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| WO-2017075178-A1 | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017075182-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | disclosed |
| US-9630987-B2 | Procedure for the preparation of abiraterone acetate and intermediates thereof | OLON S.P.A. (IT) | 2017-04-25 | — | — | US | disclosed |
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617259-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20170095570-A1 | PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-9611270-B2 | Inhibitors of CYP17A1 | UNIVERSITY OF KANSAS (US) | 2017-04-04 | — | — | US | disclosed |
| US-9608291-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20170084955-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-03-23 | — | — | US | disclosed |
| US-9598374-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2017-03-02 | — | — | US | disclosed |
| EP-2861604-B1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2017-03-01 | — | — | EP | disclosed |
| CN-103958468-B | Piperidinylnaphthylacetic acids | 弗·哈夫曼-拉罗切有限公司 | 2017-03-01 | — | — | CN | disclosed |
| US-20170044207-A1 | PROCEDURE FOR THE PREPARATION OF ABIRATERONE ACETATE AND INTERMEDIATES THEREOF | OLON S.P.A. (IT) | 2017-02-16 | — | — | US | disclosed |
| US-9567339-B2 | Primary carboxamides as BTK inhibitors | ABBVIE INC. (US) | 2017-02-14 | — | — | US | disclosed |
| WO-2017023617-A1 | SYNTHESIS AND BIOLOGICAL ACTIVITY OF 2-METHYLENE ANALOGS OF CALCITRIOL AND RELATED COMPOUNDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20170036977-A1 | SYNTHESIS AND BIOLOGICAL ACTIVITY OF 2-METHYLENE ANALOGS OF CALCITRIOL AND RELATED COMPOUNDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170029412-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-02-02 | — | — | US | disclosed |
| US-9556218-B2 | Process for the preparation of abiraterone and intermediates thereof | SCINOPHARM TAIWAN, LTD. (TW) | 2017-01-31 | — | — | US | disclosed |
| US-9556219-B2 | Procedure for the preparation of abiraterone acetate and intermediates thereof | OLON S.P.A. (IT) | 2017-01-31 | — | — | US | disclosed |
| US-20170008906-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2017002064-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-05 | — | — | WO | disclosed |
| US-9527846-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | disclosed |
| US-9526731-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-27 | — | — | US | disclosed |
| EP-3102563-A1 | CYCLOPENTENE AND CYCLOPENTADIENE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | BASF SE (DE) | 2016-12-14 | — | — | EP | disclosed |
| CN-104011018-B | Can be used for preparing the tall and erect synthetic method of Pyrrolobenzodiazepines and intermediate | 麦迪穆有限责任公司 | 2016-12-14 | — | — | CN | disclosed |
| US-20160355466-A1 | CYCLOPENTENE AND CYCLOPENTADIENE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | BASF SE (DE) | 2016-12-08 | — | — | US | disclosed |
| EP-3099701-A2 | PROCEDURE FOR THE PREPARATION OF ABIRATERONE ACETATE AND INTERMEDIATES THEREOF | OLON S.p.A. (IT) | 2016-12-07 | — | — | EP | disclosed |
| US-9512175-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160347786-A1 | PROCEDURE FOR THE PREPARATION OF ABIRATERONE ACETATE AND INTERMEDIATES THEREOF | OLON S.P.A. (IT) | 2016-12-01 | — | — | US | disclosed |
| EP-2844643-B1 | PYRIMIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9505745-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-29 | — | — | US | disclosed |
| US-20160340279-A1 | SUBSTITUTED (4'-HYDROXYPHENYL)CYCLOAKLKANE COMPOUNDS AND USES THEREOF AS SELECTIVE AGONISTS OF THE ESTROGEN RECEPTOR BETA ISOFORM | MARQUETTE UNIVERSITY (US) | 2016-11-24 | — | — | US | disclosed |
| EP-1807077-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-23 | — | — | EP | disclosed |
| WO-2016177862-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2016-11-10 | — | — | WO | disclosed |
| CN-105960395-A | Cyclopentene and cyclopentadiene compounds for controlling invertebrate pests | 巴斯夫欧洲公司 | 2016-09-21 | — | — | CN | disclosed |
| EP-2909225-B1 | PROCESS FOR THE PURIFICATION OF ABIRATERONE ACETATE | OLON SPA (IT) | 2016-09-14 | — | — | EP | disclosed |
| US-9440974-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-09-13 | — | — | US | disclosed |
| US-20160257657-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2016-09-08 | — | — | US | disclosed |
| US-20160243135-A1 | Compositions and Methods for Modification of Biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160229852-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-11 | — | — | US | disclosed |
| US-20160220633-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| WO-2016120890-A1 | AN ENANTIOSELECTIVE PROCESS FOR THE SYNTHESIS OF (2S,4R)-4-HYDROXYPIPECOLIC ACID | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-08-04 | — | — | WO | disclosed |
| US-9403776-B2 | Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9394282-B2 | Pyrazole carboxamides as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-19 | — | — | US | disclosed |
| WO-2016112284-A1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
| US-20160184267-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2016-06-30 | — | — | US | disclosed |
| WO-2016102490-A1 | CYCLIC COMPOUNDS SUBSTITUTED BY A CONDENSED RING SYSTEM | BASF SE (DE) | 2016-06-30 | — | — | WO | disclosed |
| EP-2358202-B1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2016-06-15 | — | — | EP | disclosed |
| US-9365534-B2 | Arylated camphenes, processes for their preparation and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-06-14 | — | — | US | disclosed |
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| WO-2016089833-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016089797-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016089830-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-9359354-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-06-07 | — | — | US | disclosed |
| WO-2016081589-A2 | 13-CIS-RAMBA RETINAMIDES THAT DEGRADE MNKS FOR TREATING CANCER | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2016-05-26 | — | — | WO | disclosed |
| US-20160137652-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2016-05-19 | — | — | US | disclosed |
| US-9340571-B2 | Process for the purification of abiraterone acetate | OLON S.P.A. (IT) | 2016-05-17 | — | — | US | disclosed |
| US-9343777-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-05-17 | — | — | US | disclosed |
| WO-2016073770-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016073738-A2 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016066697-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-06 | — | — | WO | disclosed |
| EP-3013848-A2 | PROCESS FOR THE PREPARATION OF ABIRATERONE AND INTERMEDIATES THEREOF | Scinopharm Taiwan, Ltd. (CN) | 2016-05-04 | — | — | EP | disclosed |
| EP-3013337-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | Abbvie Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| CN-105530932-A | Primary carboxamides as BIK inhibitors | ABBVIE INC | 2016-04-27 | — | — | CN | disclosed |
| US-9315503-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-04-19 | — | — | US | disclosed |
| WO-2016057572-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | MILLER MARK THOMAS (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160102083-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| US-20160095858-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-04-07 | — | — | US | disclosed |
| CN-102803216-B | Heterocylic antiviral compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-06 | — | — | CN | disclosed |
| EP-2991980-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2016-03-09 | — | — | EP | disclosed |
| CN-105377871-A | Preparation method of abiraterone and intermediate thereof | SCINOPHARM TAIWAN LTD | 2016-03-02 | — | — | CN | disclosed |
| US-20160052958-A1 | PROCESS FOR THE PURIFICATION OF ABIRATERONE ACETATE | OLON S.P.A. (IT) | 2016-02-25 | — | — | US | disclosed |
| US-9260371-B2 | Compositions and methods for modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-16 | — | — | US | disclosed |
| WO-2016022448-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2016-02-11 | — | — | WO | disclosed |
| US-20160031929-A1 | INHIBITORS OF CYP17A1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
| US-20160031876-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9252457-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20160024016-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2016012362-A1 | SUBSTITUTED CYANO CYCLOALKYL PENTA-2,4-DIENES, CYANO CYCLOALKYL PENT-2-EN-4-YNES, CYANO HETEROCYCLYL PENTA-2,4-DIENES AND CYANO HETEROCYCLYL PENT-2-EN-4-YNES AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
| US-20160016953-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A (IT) | 2016-01-21 | — | — | US | disclosed |
| WO-2016008862-A1 | SUBSTITUTED VINYL AND ALKYNYL CYANOCYCLOALKANOLS AND VINYL AND ALKYNYL CYANOHETEROCYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-01-21 | — | — | WO | disclosed |
| EP-2968207-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS | CHDI Foundation, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970335-A1 | MACROCYCLIC AND BICYCLIC INHIBITORS OF HEPATITIS C VIRUS | Gilead Sciences, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150376201-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150361132-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-20150344521-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344475-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-03 | — | — | US | disclosed |
| US-9199946-B2 | Pyrimidinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-01 | — | — | US | disclosed |
| US-9181242-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-11-10 | — | — | US | disclosed |
| US-20150274774-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2015-10-01 | — | — | US | disclosed |
| US-9145441-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145413-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-09-29 | — | — | US | disclosed |
| US-9139584-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-09-22 | — | — | US | disclosed |
| US-9127019-B2 | Cortistatin analogues and synthesis thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150246917-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2015-09-03 | — | — | US | disclosed |
| US-9120814-B2 | Compounds with embedded benzopyran motif for core structures and preparation method thereof | SNU R&DB FOUNDATION (KR) | 2015-09-01 | — | — | US | disclosed |
| US-9120757-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-09-01 | — | — | US | disclosed |
| EP-2909225-A1 | PROCESS FOR THE PURIFICATION OF ABIRATERONE ACETATE | OLON S.p.A. (IT) | 2015-08-26 | — | — | EP | disclosed |
| EP-2760840-B1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| WO-2015114518-A2 | PROCEDURE FOR THE PREPARATION OF ABIRATERONE ACETATE AND INTERMEDIATES THEREOF | OLON S.P.A. (IT) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015114157-A1 | CYCLOPENTENE AND CYCLOPENTADIENE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | BASF SE (DE) | 2015-08-06 | — | — | WO | disclosed |
| CN-102670605-B | Suppress the kinase whose method of C KIT | JANSSEN PHARMACEUTICA N. V. (BE) | 2015-07-29 | — | — | CN | disclosed |
| US-9090653-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090627-B2 | Batrachotoxin analogues, compositions, uses, and preparation thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090661-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2015-07-28 | — | — | US | disclosed |
| CN-104781261-A | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES INC | 2015-07-15 | — | — | CN | disclosed |
| US-20150188192-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-07-02 | — | — | US | disclosed |
| EP-1812031-B1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | UNIV CALIFORNIA (US) | 2015-06-24 | — | — | EP | disclosed |
| US-9062055-B2 | Fused pyrrole derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062092-B2 | Macrocyclic inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| CN-104703991-A | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES INC | 2015-06-10 | — | — | CN | disclosed |
| CN-104662033-A | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES INC | 2015-05-27 | — | — | CN | disclosed |
| US-9029373-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-05-12 | — | — | US | disclosed |
| US-20150111921-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEROF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-04-23 | — | — | US | disclosed |
| EP-2861601-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | Gilead Sciences, Inc. (US) | 2015-04-22 | — | — | EP | disclosed |
| EP-2861604-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | Gilead Sciences, Inc. (US) | 2015-04-22 | — | — | EP | disclosed |
| CN-104540830-A | Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase | HOFFMANN LA ROCHE | 2015-04-22 | — | — | CN | disclosed |
| US-20150105376-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2015-04-16 | — | — | US | disclosed |
| EP-2859009-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | Gilead Sciences, Inc. (US) | 2015-04-15 | — | — | EP | disclosed |
| EP-2858994-A1 | PYRAZOLOPYRIMIDONE AND PYRAZOLOPYRIDONE INHIBITORS OF TANKYRASE | F. Hoffmann-La Roche AG (CH) | 2015-04-15 | — | — | EP | disclosed |
| US-9006231-B2 | Cephalotaxus esters, methods of synthesis, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2015-04-14 | — | — | US | disclosed |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-02 | — | — | US | disclosed |
| US-20150080375-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-03-19 | — | — | US | disclosed |
| EP-2844643-A1 | PYRIMIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | Bristol-Myers Squibb Company (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20150065505-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150056503-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-02-26 | — | — | US | disclosed |
| US-20150056699-A1 | SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-02-26 | — | — | US | disclosed |
| US-8962608-B2 | Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20150038728-A1 | NOVEL ARYLATED CAMPHENES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2015-02-05 | — | — | US | disclosed |
| US-8946430-B2 | Quinolinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-03 | — | — | US | disclosed |
| US-8933091-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| US-20150005279-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005489-A1 | PROCESS FOR THE PREPARATION OF ABIRATERONE AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN, LTD. (CN) | 2015-01-01 | — | — | US | disclosed |
| WO-2014210255-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014207567-A2 | PROCESS FOR THE PREPARATION OF ABIRATERONE AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN, LTD. (TW) | 2014-12-31 | — | — | WO | disclosed |
| US-20140371138-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2014-12-18 | — | — | US | disclosed |
| CN-101903310-B | Method for producing organic compound | M TECH CO LTD | 2014-12-17 | — | — | CN | disclosed |
| US-8912318-B2 | Nucleobase-functionalized conformationally restricted nucleotides and oligonucleotides for targeting nucleic acids | UNIVERSITY OF IDAHO (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140364412-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-11 | — | — | US | disclosed |
| US-20140364411-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-11 | — | — | US | disclosed |
| US-8907094-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-09 | — | — | US | disclosed |
| US-20140343055-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A (IT) | 2014-11-20 | — | — | US | disclosed |
| US-20140336158-A1 | NK1 ANTAGONISTS | TERSERA THERAPEUTICS LLC | 2014-11-13 | — | — | US | disclosed |
| WO-2014177982-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-11-06 | — | — | WO | disclosed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323346-A1 | BINDING AGENT | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2014-10-30 | — | — | US | disclosed |
| US-20140323470-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-10-30 | — | — | US | disclosed |
| US-8871759-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140315904-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2014159218-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS | CHDI FOUNDATION, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140296514-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2014-10-02 | — | — | US | disclosed |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2014-09-18 | — | — | US | disclosed |
| WO-2014145095-A1 | MACROCYCLIC AND BICYCLIC INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8835431-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-20140248299-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-09-04 | — | — | US | disclosed |
| CN-102427729-B | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME | 2014-09-03 | — | — | CN | disclosed |
| US-20140243309-A1 | CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-28 | — | — | US | disclosed |
| US-20140243314-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-28 | — | — | US | disclosed |
| CN-104011018-A | SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES | SPIROGEN SARL | 2014-08-27 | — | — | CN | disclosed |
| US-20140235641-A1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | INTERVET INC. | 2014-08-21 | — | — | US | disclosed |
| CN-103998444-A | Adhesive agent | CANCER THERAPEUTICS CRC PTY LTD | 2014-08-20 | — | — | CN | disclosed |
| EP-2760840-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8796299-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| EP-2758389-A1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2758377-A1 | CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-07-30 | — | — | EP | disclosed |
| CN-103958468-A | Piperidinylnaphthylacetic acids | HOFFMANN LA ROCHE | 2014-07-30 | — | — | CN | disclosed |
| US-8791101-B2 | Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| WO-2014109712-A1 | PALLADIUM-CATALYZED ASYMMETRIC (HETERO)ARYLATION AND VINYLATION OF KETONE ENOLATES TO PRODUCE TERTIARY STEREOCENTERS AT ALPHA(α)-POSITION | NANAYNG TECHNOLOGICAL UNIVERSITY (SG) | 2014-07-17 | — | — | WO | disclosed |
| US-20140171410-A1 | Batrachotoxin Analogues, Compositions, Uses, and Preparation Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171416-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2014-06-19 | — | — | US | disclosed |
| EP-2736919-A2 | NOVEL 17ß-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS | The Regents of the University of California (US) | 2014-06-04 | — | — | EP | disclosed |
| US-20140148412-A1 | NOVEL 17B-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CLAIFORNIA (US) | 2014-05-29 | — | — | US | disclosed |
| EP-2375904-B1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-05-28 | — | — | EP | disclosed |
| US-8729069-B2 | Tetrahydropyridine, tetrahydroazepine, and dihydropyrrole derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722938-B2 | Arylated camphenes, processes for their preparation and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANYOF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2014-05-13 | — | — | US | disclosed |
| WO-2014064032-A1 | PROCESS FOR THE PURIFICATION OF ABIRATERONE ACETATE | OLON S.P.A. (IT) | 2014-05-01 | — | — | WO | disclosed |
| EP-1984337-B1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-2217569-B1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-16 | — | — | EP | disclosed |
| US-8697716-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-15 | — | — | US | disclosed |
| US-8680278-B2 | Enantioselective process for preparing a substituted alkanoic acid | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-25 | — | — | US | disclosed |
| US-20140030221-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2014-01-30 | — | — | US | disclosed |
| US-8637555-B2 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20140005225-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-02 | — | — | US | disclosed |
| US-20130344029-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2013-12-26 | — | — | US | disclosed |
| US-20130344527-A1 | Compositions and Methods for Modification of Biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-12-26 | — | — | US | disclosed |
| US-20130344030-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2013-12-26 | — | — | US | disclosed |
| US-20130337581-A1 | NUCLEOBASE-FUNCTIONALIZED CONFORMATIONALLY RESTRICTED NUCLEOTIDES AND OLIGONUCLEOTIDES FOR TARGETING NUCLEIC ACIDS | UNIVERSITY OF IDAHO (US) | 2013-12-19 | — | — | US | disclosed |
| WO-2013185093-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2013-12-12 | — | — | WO | disclosed |
| WO-2013185090-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2013-12-12 | — | — | WO | disclosed |
| WO-2013185103-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2013-12-12 | — | — | WO | disclosed |
| WO-2013182546-A1 | PYRAZOLOPYRIMIDONE AND PYRAZOLOPYRIDONE INHIBITORS OF TANKYRASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-12 | — | — | WO | disclosed |
| EP-2397138-B1 | Aromatic amide derivatives as C-KIT kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-11 | — | — | EP | disclosed |
| US-8592498-B2 | Method for producing organic compound and organic compound obtained by the method | M. TECHNIQUE CO., LTD. (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8591943-B2 | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2660241-A2 | C-17-HETEROARYL STEROIDAL COMPOUNDS AS INHIBITORS OF CYP11B, CYP17, AND/OR CYP21 | BioMarin Pharmaceutical Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| EP-2651916-A2 | C-17-HETEROARYL STEROIDAL COMPOUNDS AS INHIBITORS OF CYP11B, CYP17, AND/OR CYP21 | BioMarin Pharmaceutical Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8557847-B2 | Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| WO-2013151877-A1 | PYRIMIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (CA) | 2013-09-26 | — | — | US | disclosed |
| EP-2135867-B1 | Trans-9, 10-dehydroepothilone C and trans-9, 10-dehydroepothilone D, analogs thereof and methods of making the same | KOSAN BIOSCIENCES INC (US) | 2013-09-25 | — | — | EP | disclosed |
| US-8536174-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-20130225825-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-8518908-B2 | Nucleobase-functionalized conformationally restricted nucleotides and oligonucleotides for targeting of nucleic acids | UNIVERSITY OF IDAHO (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2364311-B1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI SA (FR) | 2013-07-03 | — | — | EP | disclosed |
| US-8475765-B2 | Hydroxyalkyl starch derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| US-8470819-B2 | Benzimidazole and aza-benzimidazole carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8466142-B2 | Cephalotaxus esters, methods of synthesis, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-06-18 | — | — | US | disclosed |
| US-20130150343-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | US | disclosed |
| US-20130150361-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | US | disclosed |
| US-8461298-B2 | Compositions and methods for modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-11 | — | — | US | disclosed |
| WO-2013075167-A1 | BINDING AGENT | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2013-05-30 | — | — | WO | disclosed |
| EP-2593107-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-8431558-B2 | Compositions and methods for modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-04-30 | — | — | US | disclosed |
| WO-2013048942-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013041042-A1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013040863-A1 | CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013028999-A1 | SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013019711-A2 | NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | WO | disclosed |
| CN-101142218-B | Pyrrolopyrimidines useful as inhibitors of protein kinase | VERTEX PHARMA | 2013-02-06 | — | — | CN | disclosed |
| US-8367706-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367679-B2 | Biaryl carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| WO-2013014579-A1 | PROCESS FOR THE BORYLATION OF ORGANOHALIDES | BASF SE (DE) | 2013-01-31 | — | — | WO | disclosed |
| US-20130023503-A1 | NK1 ANTAGONISTS | OPKO HEALTH, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-20130023689-A1 | PROCESS FOR THE BORYLATION OF ORGANOHALIDES | BASF SE (DE) | 2013-01-24 | — | — | US | disclosed |
| CN-101497671-B | Hydroxyalkyl starch derivatives | PRESENIUS KABI DEUTSCHLAND GMBH | 2013-01-16 | — | — | CN | disclosed |
| EP-2528914-A1 | FURO [3, 2 -B]PYRANE DERIVATIVES USEFUL IN THE SYNTHESIS OF HALICHONDRIN B ANALOGS | Eisai R&D Management Co., Ltd. (JP) | 2012-12-05 | — | — | EP | disclosed |
| CN-102803216-A | Heterocyclic antiviral compounds | HOFFMANN LA ROCHE | 2012-11-28 | — | — | CN | disclosed |
| US-20120295862-A1 | NUCLEOBASE-FUNCTIONALIZED CONFORMATIONALLY RESTRICTED NUCLEOTIDES AND OLIGONUCLEOTIDES FOR TARGETING OF NUCLEIC ACIDS | The Univeristy of Idaho | 2012-11-22 | — | — | US | disclosed |
| EP-2143736-B1 | Hydroxyalkyl starch derivatives | FRESENIUS KABI DE GMBH (DE) | 2012-11-07 | — | — | EP | disclosed |
| EP-2166846-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| CN-102711473-A | Bruton's tyrosine kinase inhibitors | BIOGEN IDEC INC | 2012-10-03 | — | — | CN | disclosed |
| US-20120245366-A1 | NOVEL ARYLATED CAMPHENES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANYOF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2012-09-27 | — | — | US | disclosed |
| EP-2501669-A2 | NOVEL ARYLATED CAMPHENES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (IL) | 2012-09-26 | — | — | EP | disclosed |
| US-8273895-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| CN-102670605-A | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV | 2012-09-19 | — | — | CN | disclosed |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120177988-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-07-12 | — | — | US | disclosed |
| EP-2015748-B1 | A C-Kit kinase inhibitor for use in the treatment of gastrointestinal stromal tumor or mastocytosis | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-04 | — | — | EP | disclosed |
| WO-2012083112-A2 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| CN-102510864-A | Antiviral Heterocyclic Compounds | HOFFMANN LA ROCHE | 2012-06-20 | — | — | CN | disclosed |
| CN-102498100-A | Heterocyclic antiviral compounds | HOFFMANN LA ROCHE | 2012-06-13 | — | — | CN | disclosed |
| US-8193191-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-05 | — | — | US | disclosed |
| US-8178517-B2 | 6-methylvitamin D3 analogs and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| CN-101437514-B | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA NV | 2012-04-25 | — | — | CN | disclosed |
| US-8153624-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP (NJ) | 2012-04-05 | — | — | US | disclosed |
| US-8143287-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120070731-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-03-22 | — | — | US | disclosed |
| CN-101610768-B | Methods of inhibiting C KIT kinase | JANSSEN PHARMACEUTICA NV | 2012-03-21 | — | — | CN | disclosed |
| EP-2417138-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | Schering Corporation (US) | 2012-02-15 | — | — | EP | disclosed |
| EP-2410844-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Merck Sharp & Dohme Corp. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2012009194-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| CN-101340909-B | Method of inhibiting flt3 kinase | JANSSEN PHARMACEUTICA NV | 2012-01-11 | — | — | CN | disclosed |
| US-8093302-B2 | Substituted tetralins as selective estrogen receptor-β agonists | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| WO-2011163195-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-12-29 | — | — | WO | disclosed |
| EP-2178851-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20110312979-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-12-22 | — | — | US | disclosed |
| EP-1993554-B1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | disclosed |
| EP-2375904-A1 | BIARYL CARBOXAMIDES | Merck Sharp & Dohme Corp. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-1501830-B1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-05 | — | — | EP | disclosed |
| EP-2367830-A1 | 1-OXA-8-AZASPIRO [4, 5] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230498-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | disclosed |
| EP-2364311-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI (FR) | 2011-09-14 | — | — | EP | disclosed |
| US-20110213123-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-09-01 | — | — | US | disclosed |
| EP-1882686-B1 | Pyrrolidine and piperidine derivates as NK1 antagonists | OPKO HEALTH INC (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-2361246-A1 | OXOPIPERIDINYL AND PYRANYL SULFONAMIDES AS AMPA POTENTIATORS | Pfizer Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| US-20110190323-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011094339-A1 | FURO [3, 2 -B] PYRANE DERIVATIVES USEFUL IN THE SYNTHESIS OF HALICHONDRIN B ANALOGS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-04 | — | — | WO | disclosed |
| US-20110178199-A1 | METHOD FOR PRODUCING ORGANIC COMPOUND AND ORGANIC COMPOUND OBTAINED BY THE METHOD | M. TECHNIQUE CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110172297-A1 | Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2011-07-14 | — | — | US | disclosed |
| EP-2334686-A2 | CORTISTATIN ANALOGUES AND SYNTHESES THEROF | President and Fellows of Harvard College (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20110136824-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E | 2011-06-09 | — | — | US | disclosed |
| US-7956050-B2 | Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| WO-2011061744-A2 | NOVEL ARYLATED CAMPHENES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2011-05-26 | — | — | WO | disclosed |
| US-20110098468-A1 | NK1 ANTAGONISTS | OPKO HEALTH, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| EP-1140085-B1 | AZABICYCLOALKANES AS CCR5 MODULATORS | PHIVCO UK LTD (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-20110082123-A1 | 6-Methylvitamin D3 Analogs and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011041599-A2 | 6-METHYLVITAMIN D3 ANALOGS AND THEIR USES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-04-07 | — | — | WO | disclosed |
| US-7915260-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-03-29 | — | — | US | disclosed |
| US-20110071097-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-03-24 | — | — | US | disclosed |
| US-7910623-B2 | Synthesis of scabronines and analogues thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-03-22 | — | — | US | disclosed |
| WO-2011032034-A2 | NUCLEOBASE-FUNCTIONALIZED CONFORMATIONALLY RESTRICTED NUCLEOTIDES AND OLIGONUCLEOTIDES FOR TARGETING NUCLEIC ACIDS | UNIVERSITY OF IDAHO (US) | 2011-03-17 | — | — | WO | disclosed |
| US-7902366-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20110054152-A1 | Hydroxyalkyl Starch Derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| EP-1901731-B1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20110046114-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110015400-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015184-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110009485-A9 | SYNTHESIS OF SCABRONINES AND ANALOGUES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| US-20100323965-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2260041-A2 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | Sloan Kettering Institute For Cancer Research (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-1858857-B1 | AZABICYCLOALKANE DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | LILLY CO ELI (US) | 2010-12-08 | — | — | EP | disclosed |
| CN-101903310-A | Method for producing organic compound and organic compound obtained thereby | M TECH CO LTD | 2010-12-01 | — | — | CN | disclosed |
| EP-1280764-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2010-11-24 | — | — | EP | disclosed |
| US-7816535-B2 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7815893-B2 | Hydroxyalkyl starch derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256148-A1 | USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-07 | — | — | US | disclosed |
| US-7807619-B2 | cycloalkyne compounds reacting with an azide moiety on a target biomolecule, by biochemical conjugation; for its application in vivo (on the cell surface or intracellularly) or in vitro (synthesis of peptides); labeling | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-05 | — | — | US | disclosed |
| WO-2010111483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2010-09-30 | — | — | US | disclosed |
| US-7795279-B2 | Method of inhibiting FLT3 kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| EP-2222298-A1 | USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER | Janssen Pharmaceutica N.V. (BE) | 2010-09-01 | — | — | EP | disclosed |
| US-7786159-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-2217569-A1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | Janssen Pharmaceutica N.V. (BE) | 2010-08-18 | — | — | EP | disclosed |
| EP-2216312-A1 | PROCESS FOR PRODUCING ORGANIC COMPOUND AND ORGANIC COMPOUND OBTAINED BY THE SAME | M Technique Co., Ltd. (JP) | 2010-08-11 | — | — | EP | disclosed |
| US-7763739-B2 | bidentante optionally N-containing P-ligands embracing a two-ring-system; for transition metal complexes to be used as catalysts | Evonik Degussa, GmbH (DE) | 2010-07-27 | — | — | US | disclosed |
| EP-1610789-B1 | BICYCLIC PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2010-07-21 | — | — | EP | disclosed |
| WO-2010077624-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
| CN-101010323-B | Bicyclononene derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD | 2010-06-16 | — | — | CN | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100137347-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2010058318-A1 | 1-OXA-8-AZASPIRO [4, 5 ] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS | PFIZER INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| EP-1371646-B1 | ARYL-SUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION COMPRISING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2010-05-19 | — | — | EP | disclosed |
| WO-2010049635-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | WO | disclosed |
| EP-2178851-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | Eli Lilly & Company (US) | 2010-04-28 | — | — | EP | disclosed |
| US-7705042-B2 | Class of arylamide compounds useful as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7700798-B1 | Erogorgiaene congeners and methods and intermediates useful in the preparation of same | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-04-20 | — | — | US | disclosed |
| WO-2010038167-A1 | OXOPIPERIDINYL AND PYRANYL SULFONAMIDES AS AMPA POTENTIATORS | PFIZER INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-2162455-A2 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | Glaxo Group Limited (GB) | 2010-03-17 | — | — | EP | disclosed |
| WO-2010024930-A2 | CORTISTATIN ANALOGUES AND SYNTHESES THEROF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-03-04 | — | — | WO | disclosed |
| EP-2154160-A1 | Hydroxyalkyl starch derivatives | Fresenius Kabi Deutschland GmbH (DE) | 2010-02-17 | — | — | EP | disclosed |
| US-7662837-B2 | 4-cyano-1H-imidazole-2-carboxylic acid {2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl}-amide; protein tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-16 | — | — | US | disclosed |
| US-20100035865-A1 | Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| EP-1805141-B1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (GB) | 2010-01-20 | — | — | EP | disclosed |
| EP-2143736-A1 | Hydroxyalkyl starch derivatives | Fresenius Kabi Deutschland GmbH (DE) | 2010-01-13 | — | — | EP | disclosed |
| EP-2142505-A1 | SULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Pfizer, Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
| US-7645781-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER INC (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645755-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICAL N.V. (BE) | 2010-01-12 | — | — | US | disclosed |
| US-7642270-B2 | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-05 | — | — | US | disclosed |
| US-20090326015-A1 | COMPOUNDS WITH EMBEDDED BENZOPYRAN MOTIF FOR CORE STRUCTURES AND PREPARATION METHOD THEREOF | SNU R&DB FOUNDATION (KR) | 2009-12-31 | — | — | US | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| US-7638629-B2 | Piperidines and related compounds for treatment of alzheimer's disease | Merck Sharp & Dohme Ltd, (GB) | 2009-12-29 | — | — | US | disclosed |
| EP-2135867-A1 | Trans-9, 10-dehydroepothilone C and trans-9, 10-dehydroepothilone D, analogs thereof and methods of making the same | Kosan Biosciences Incorporated (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-1562941-B1 | TRANS-9,10-DEHYDROEPOTHILONE C AND D, ANALOGS THEREOF AND METHOS OF MAKING THE SAME | KOSAN BIOSCIENCES INC (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2135868-A1 | TRANS-9, 10-DEHYDROEPOTHILONE C AND D, ANALOGS THEREOF AND METHODS OF MAKING THE SAME | Kosan Biosciences Incorporated (US) | 2009-12-23 | — | — | EP | disclosed |
| CN-101610768-A | Methods of inhibiting C KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-23 | — | — | CN | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| WO-2009148654-A2 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2009-12-10 | — | — | WO | disclosed |
| US-7622468-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622489-B2 | Kinesin spindle protein inhibitor; antiproliferative agents; anticancer agents; 4-(2,5-difluorophenyl)-N-3-fluoropyrrolidin-3-yl)-2-hydroxymethyl-2-phenyl-2,5-dihydro-1N-pyrrol-1-carboxamide | MERCK & CO., INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1398328-B1 | Hydroxyalkyl starch derivatives | FRESENIUS KABI DE GMBH (DE) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009137337-A1 | STEREOSELECTIVE SYNTHESIS OF 17-α -AND 17-β -ARYL STEROIDAL COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-1723140-B1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-11-04 | — | — | EP | disclosed |
| EP-1515724-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-10-21 | — | — | EP | disclosed |
| US-7598386-B2 | Sulphones which modulate the action of gamma-secretase | MERCK SHARP & DOHME LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7595344-B2 | Sulphones which modulate the action of gamma secretase | MERCK SHARP & DOHME LIMITED (GB) | 2009-09-29 | — | — | US | disclosed |
| CN-100528866-C | Indoles, azaindoles and related heterocyclic 4-alkenyl piperidine amides | BRISTOL MYERS SQUIBB CO (US) | 2009-08-19 | — | — | CN | disclosed |
| CN-100528871-C | Benzothiazole derivatives as adenosine receptor ligands | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | CN | disclosed |
| EP-2086551-A2 | THROMBOPOIETIN MIMETICS | Stategics, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090197913-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | BAUMANN CHRISTIAN ANDREW | 2009-08-06 | — | — | US | disclosed |
| CN-101497671-A | Hydroxyalkyl starch derivatives | FRESENIUS KABI DE GMBH (DE) | 2009-08-05 | — | — | CN | disclosed |
| EP-1807407-B1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | EP | disclosed |
| US-20090186927-A1 | TRANS-9,10-DEHYDROEPOTHILONE C AND D, ANALOGS THEREOF AND METHODS OF MAKING THE SAME | KOSAN BIOSCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186940-A1 | Synthesis of Scabronines and Analogues Thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2009-07-23 | — | — | US | disclosed |
| US-20090181971-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. | 2009-07-16 | — | — | US | disclosed |
| WO-2009075778-A2 | NONPEPTIDIC INHIBITORS OF CRUZAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090131419-A1 | Sulphones which modulate the action of gamma secretase | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| CN-101437514-A | Inhibidores of C-FMS cinasa | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-20 | — | — | CN | disclosed |
| US-20090124804-A1 | Enantioselective process for preparing a substituted alkanoic acid | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-14 | — | — | US | disclosed |
| US-20090118260-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| WO-2009058314-A1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058801-A1 | USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-07 | — | — | WO | disclosed |
| CN-100480274-C | Hydroxyalkyl starch derivatives | FRESENIUS KABI DE GMBH (DE) | 2009-04-22 | — | — | CN | disclosed |
| CN-101400653-A | 11-beta HSD1 inhibitors | WYETH CORP (US) | 2009-04-01 | — | — | CN | disclosed |
| EP-1581497-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090068738-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| WO-2009012125-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| EP-2015748-A2 | METHOD OF INHIBITING C KIT KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
| CN-101340909-A | Method of inhibiting flt3 kinase | JANSSEN PHARMACEUTICA NV (BE) | 2009-01-07 | — | — | CN | disclosed |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080312242-A1 | 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-12-18 | — | — | US | disclosed |
| US-20080306264-A1 | bidentante optionally N-containing P-ligands embracing a two-ring-system; for transition metal complexes to be used as catalysts | DEGUSSA AG (DE) | 2008-12-11 | — | — | US | disclosed |
| WO-2008145688-A2 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 2008-12-04 | — | — | WO | disclosed |
| EP-1993554-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-11-26 | — | — | EP | disclosed |
| US-7449485-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES INC. (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1984337-A2 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1983993-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080261999-A1 | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-23 | — | — | US | disclosed |
| EP-1981848-A2 | 11-BETA HSD1 INHIBITORS | Wyeth (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2008120093-A1 | SULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080234305-A1 | Novel Tetrahydropyridine Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-25 | — | — | US | disclosed |
| US-7427613-B2 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-23 | — | — | US | disclosed |
| US-7419990-B2 | Piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080207595-A9 | Psychological disorders; analgesics; hyperactivity; eating disorders | AMR TECHNOLOGY, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1948605-A2 | MODULATORS OF THE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008088690-A2 | A PROCESS FOR PREPARING DIAZABICYCLO[3.3.1] NONANE COMPOUNDS | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-1613585-A4 | COMPOUNDS AND METHODS FOR USE IN TREATING NEOPLASIA AND CANCER BASED UPON INHIBITORS OF ISOPRENYLCYSTEINE METHYLTRANSFERASE | PURDUE RESEARCH FOUNDATION (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1937681-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | disclosed |
| CN-101208082-A | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK & CO INC (US) | 2008-06-25 | — | — | CN | disclosed |
| WO-2008072801-A1 | COMPOUNDS WITH EMBEDDED BENZOPYRAN MOTIF FOR CORE STRUCTURES AND PREPARATION METHOD THEREOF | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2008-06-19 | — | — | WO | disclosed |
| US-20080146572-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080139621-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008070583-A2 | THROMBOPOIETIN MIMETICS | STATEGICS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080114007-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-15 | — | — | US | disclosed |
| US-7371748-B2 | Benzothiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| WO-2008055013-A2 | 5-OXO-5,8 - DIHYDRO - PYRIDO - PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-08 | — | — | WO | disclosed |
| US-20080103311-A1 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| CN-100384837-C | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORP (US) | 2008-04-30 | — | — | CN | disclosed |
| EP-1912989-A2 | TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | disclosed |
| US-7358251-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1904069-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR Technology, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-1592698-B1 | PHOSPHINE COMPOUND, INTERMEDIATE, PALLADIUM-COMPLEX, AND USE THEREOF | TAKASAGO PERFUMERY CO LTD (JP) | 2008-03-26 | — | — | EP | disclosed |
| EP-1901731-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| US-7348440-B2 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1898912-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1636223-B1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | disclosed |
| CN-101142218-A | Pyrrolopyrimidines useful as inhibitors of protein kinase | VERTEX PHARMA (US) | 2008-03-12 | — | — | CN | disclosed |
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-20080051402-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-28 | — | — | US | disclosed |
| EP-1610789-A4 | BICYCLIC PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1463716-B1 | PYRROLIDINE AND PIPERIDINE DERIVATES AS NK1 ANTAGONISTS | SCHERING CORP (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7329673-B2 | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1882686-A2 | Pyrrolidine and piperidine derivates as nk1 antagonists | SCHERING CORPORATION (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2008-01-24 | — | — | US | disclosed |
| US-7312333-B2 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| CN-101088998-A | Trans-9,10-dehydroepothilone c and d, analogs thereof and methods of making the same | KOSAN BIOSCIENCES INC (US) | 2007-12-19 | — | — | CN | disclosed |
| US-7304058-B2 | For therapy of Alzheimer's disease, depression | HOFFMANN-LA ROCHE INC. (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1620403-B1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-11-28 | — | — | EP | disclosed |
| EP-1858857-A1 | AZABICYCLOALKANE DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | Eli Lilly & Company (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1853578-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007124369-A2 | METHOD OF INHIBITING C KIT KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-7288567-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| US-7276520-B2 | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| EP-1833800-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| US-20070213329-A1 | Sulphones which modulate the action of gammasecretase | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| EP-1487811-B1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007092364-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007092435-A2 | 11-BETA HSD1 INHIBITORS | WYETH (US) | 2007-08-16 | — | — | WO | disclosed |
| CN-1330648-C | Trans-9, 10-dehydroepothilones C and D, analogs thereof and methods of making these compounds | KOSAN BIOSCIENCES INC (US) | 2007-08-08 | — | — | CN | disclosed |
| WO-2007087443-A2 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1812031-A2 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-01 | — | — | EP | disclosed |
| CN-101010323-A | Bicyclononene derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-01 | — | — | CN | disclosed |
| WO-2007080126-A2 | DSRNA AS INSECT CONTROL AGENT | DEVGEN N.V. (BE) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007081995-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-19 | — | — | WO | disclosed |
| EP-1807407-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1807077-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1805141-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LTD. (GB) | 2007-07-11 | — | — | EP | disclosed |
| EP-1802602-A1 | SUBSTITUTED DIPIPERDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-04 | — | — | EP | disclosed |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | US | disclosed |
| US-20070142363-A1 | Novel diazabicyclonene derivatives and use thereof | ACTELION PHARMACEUTICALS LTD (CH) | 2007-06-21 | — | — | US | disclosed |
| US-20070142379-A1 | CYCLOHEXYL DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JAIN NARESHKUMAR F | 2007-06-21 | — | — | US | disclosed |
| CN-1984877-A | Formation of tetra-substituted enamides and stereoselective reduction thereof | MERCK & CO INC (US) | 2007-06-20 | — | — | CN | disclosed |
| US-20070135406-A1 | Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-06-14 | — | — | US | disclosed |
| WO-2007061741-A2 | MODULATORS OF THE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| CN-1972912-A | Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2007-05-30 | — | — | CN | disclosed |
| EP-1613601-A4 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1313725-B1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2007-04-11 | — | — | EP | disclosed |
| CN-1946730-A | Cycloalkenylphosphine ligands and their use in catalysis | DEGUSSA (DE) | 2007-04-11 | — | — | CN | disclosed |
| EP-1383501-B1 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7199158-B2 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20070072924-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2007033232-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-22 | — | — | WO | disclosed |
| US-20070066825-A1 | Chiral ligands and their transition metal complexes | LANXESS DEUTSCHLAND GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070060577-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-15 | — | — | US | disclosed |
| US-7183445-B2 | Cyclohexyl derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V (BE) | 2007-02-27 | — | — | US | disclosed |
| WO-2007018998-A2 | TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| EP-1628662-B1 | BENZOTHIAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES RELATED TO THE ADENOSINE A2A RECEPTOR | HOFFMANN LA ROCHE (CH) | 2007-02-14 | — | — | EP | disclosed |
| US-7176199-B2 | Aryl-substituted alicyclic compound and medical composition comprising the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| WO-2007013965-A2 | SYNTHESIS OF SCABRONINES AND ANALOGUES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007011820-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021408-A1 | Psychological disorders; analgesics; eating disorders; drug abuse | AMR TECHNOLOGY, INC. (US) | 2007-01-25 | — | — | US | disclosed |
| EP-1745058-A1 | CYCLOOLEFIN PHOSPHINE LIGANDS AND THEIR USE IN CATALYSIS | Degussa GmbH (DE) | 2007-01-24 | — | — | EP | disclosed |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | THOMAS RICHARD C | 2007-01-18 | — | — | US | disclosed |
| US-20070004803-A1 | Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase | PURDUE RESEARCH FOUNDATION (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2007002557-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| CN-1890239-A | Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain | ACTELION PHARMACEUTICALS LTD (CH) | 2007-01-03 | — | — | CN | disclosed |
| US-20060293364-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK & CO., INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006138155-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | disclosed |
| EP-1734942-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-7151098-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| EP-1729755-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1578724-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-11-29 | — | — | EP | disclosed |
| US-7141588-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1723140-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| CN-1867568-A | Diazabicyclononene derivatives and their use as renin inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-22 | — | — | CN | disclosed |
| WO-2006120472-A2 | NOVEL BETA-STEROID COMPOUNDS | GUY'S AND ST THOMAS'NHS FOUNDATION TRUST (GB) | 2006-11-16 | — | — | WO | disclosed |
| CN-1863773-A | Tetrahydropyridine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-15 | — | — | CN | disclosed |
| US-7129367-B2 | Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20060235044-A1 | Azabicyclononene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-10-19 | — | — | US | disclosed |
| US-20060235056-A1 | Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-10-19 | — | — | US | disclosed |
| EP-1478629-B1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN CO LLC (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20060223795-A1 | Novel diazabicyclononene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-10-05 | — | — | US | disclosed |
| EP-1372653-B1 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20060217371-A1 | Diazabicyclononene and tetrahydropyriddine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-09-28 | — | — | US | disclosed |
| US-20060217562-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060205768-A1 | Tropane derivatives and their use as ace inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-09-14 | — | — | US | disclosed |
| WO-2006096358-A1 | AZABICYCLOALKANE DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-09-14 | — | — | WO | disclosed |
| US-20060199815-A1 | NK1 antagonists | TERSERA THERAPEUTICS LLC | 2006-09-07 | — | — | US | disclosed |
| US-20060194780-A1 | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2006-08-31 | — | — | US | disclosed |
| CN-1826116-A | Piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO INC (US) | 2006-08-30 | — | — | CN | disclosed |
| WO-2006088716-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060189623-A1 | Inhibitors of c-fms kinase | ILLIG CARL R | 2006-08-24 | — | — | US | disclosed |
| EP-1692132-A2 | AZABICYCLOOCTENE AND OTHER TETRAHYDROPYRIDINE DERIVATIVES WITH A NEW SIDE-CHAIN | Actelion Pharmaceuticals Ltd. (CH) | 2006-08-23 | — | — | EP | disclosed |
| US-20060183904-A1 | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2006-08-17 | — | — | US | disclosed |
| US-20060166895-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (NOW NAMED PHARMACIA CORPORATION, WHICH IS A WHOLLY OWNED SUBSIDIARY OF PFIZER, INC (US) | 2006-07-27 | — | — | US | disclosed |
| EP-1683794-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | Arena Pharmaceuticals, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1680427-A1 | DIAZABICYCLONONENE AND TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-07-19 | — | — | EP | disclosed |
| EP-1678176-A1 | DIAZABICYCLONONENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
| US-20060148812-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | disclosed |
| US-20060148791-A1 | Glutamate receptor antagonists | ADAM GEO | 2006-07-06 | — | — | US | disclosed |
| EP-1673341-A1 | TETRAHYDROPYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-06-28 | — | — | EP | disclosed |
| US-7067511-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| CN-1791405-A | Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine A2a receptor | HOFFMANN LA ROCHE (CH) | 2006-06-21 | — | — | CN | disclosed |
| CN-1791607-A | Chiral ligands and transition metal complexes thereof | LANXESS DEUTSCHLAND GMBH (DE) | 2006-06-21 | — | — | CN | disclosed |
| CN-1791600-A | Benzothiazole derivatives as adenosine receptor ligands | HOFFMANN LA ROCHE (CH) | 2006-06-21 | — | — | CN | disclosed |
| US-20060128963-A1 | Piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2006-06-15 | — | — | US | disclosed |
| EP-1017675-B1 | HIGHLY LIPOPHILIC CAMPTOTHECIN DERIVATIVES | BIONUMERIK PHARMACEUTICALS INC (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1599469-B1 | TETRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARM INC (US) | 2006-06-07 | — | — | EP | disclosed |
| CN-1780838-A | Azabicyclononene derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2006-05-31 | — | — | CN | disclosed |
| CN-1780833-A | Tropane derivatives and their use as ace inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2006-05-31 | — | — | CN | disclosed |
| CN-1780836-A | Novel diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2006-05-31 | — | — | CN | disclosed |
| CN-1780663-A | 9-azabicyclononene derivatives with a heteroatom in the 3-position as renin inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2006-05-31 | — | — | CN | disclosed |
| US-20060110782-A1 | cycloalkyne compounds reacting with an azide moiety on a target biomolecule, by biochemical conjugation; for its application in vivo (on the cell surface or intracellularly) or in vitro (synthesis of peptides); labeling | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-05-25 | — | — | US | disclosed |
| US-7049311-B1 | Pyrrolbenzodiazepines | SPIROGEN LIMITED (GB) | 2006-05-23 | — | — | US | disclosed |
| US-7049320-B2 | Drugs for treating physiological disorder, respiratory disorders, inflammatory disease, skin disorder, and antidepressants, treating bipolar disorder, drug abuse, drug dependence, gastrointestinal disorder, atherosclerosis | SCHERING CORPORATION (US) | 2006-05-23 | — | — | US | disclosed |
| US-20060105997-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2006-05-18 | — | — | US | disclosed |
| WO-2006050262-A2 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060100201-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | US | disclosed |
| WO-2006047277-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006047504-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
| US-7038084-B2 | Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-05-02 | — | — | US | disclosed |
| WO-2006043064-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2006-04-27 | — | — | WO | disclosed |
| EP-1648457-A2 | PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| CN-1764458-A | Bicyclic piperidine derivatives as the melanocortin-4 receptor agonist | MERCK & CO INC (US) | 2006-04-26 | — | — | CN | disclosed |
| US-7030115-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES (US) | 2006-04-18 | — | — | US | disclosed |
| US-7026485-B2 | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-04-11 | — | — | US | disclosed |
| US-7026333-B1 | Retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20060074085-A1 | N-sulfonylurea apoptosis promoters | ABBVIE INC. | 2006-04-06 | — | — | US | disclosed |
| WO-2006036527-A1 | SUBSTITUTED DIPIPERDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069123-A1 | Substituted dipiperidine CCR2 antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-30 | — | — | US | disclosed |
| US-7018998-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1636223-A1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. Hoffman-la Roche AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| US-7015235-B2 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20060058542-A1 | Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-16 | — | — | US | disclosed |
| US-20060058327-A1 | Kinesin spindle protein inhibitor; antiproliferative agents; anticancer agents; 4-(2,5-difluorophenyl)-N-3-fluoropyrrolidin-3-yl)-2-hydroxymethyl-2-phenyl-2,5-diphdro-1N-pyrrol-1-carboxamide | MERCK SHARP & DOHME CORP. | 2006-03-16 | — | — | US | disclosed |
| EP-1633692-A2 | CYCLOHEXYL DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-15 | — | — | EP | disclosed |
| US-20060052611-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2006-03-09 | — | — | US | disclosed |
| EP-1628662-A1 | BENZOTHIAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES RELATED TO THE ADENOSINE A2A RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-01 | — | — | EP | disclosed |
| US-20060040974-A1 | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-02-23 | — | — | US | disclosed |
| US-20060035935-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | GOULET MARK T | 2006-02-16 | — | — | US | disclosed |
| EP-1622564-A2 | DIAZABICYCLONONENE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-08 | — | — | EP | disclosed |
| EP-1622907-A1 | AZABICYCLONONENE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-08 | — | — | EP | disclosed |
| EP-1622906-A1 | DIAZABICYCLONONENE AND TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-08 | — | — | EP | disclosed |
| EP-1622901-A1 | TROPANE DERIVATIVES AND THEIR USE AS ACE INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-08 | — | — | EP | disclosed |
| EP-1620403-A1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-01 | — | — | EP | disclosed |
| US-20060020009-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-01-26 | — | — | US | disclosed |
| US-20060014790-A1 | Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-01-12 | — | — | US | disclosed |
| EP-1613585-A2 | COMPOUNDS AND METHODS FOR USE IN TREATING NEOPLASIA AND CANCER BASED UPON INHIBITORS OF ISOPRENYLCYSTEINE METHYLTRANSFERASE | PURDUE RESEARCH FOUNDATION (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1613601-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co. Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1610789-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-1031563-B1 | SULFONYL DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-12-28 | — | — | EP | disclosed |
| CN-1711259-A | Trans-9, 10-dehydroepothilones C and D, analogs thereof and methods of making these compounds | KOSAN BIOSCIENCES INC (US) | 2005-12-21 | — | — | CN | disclosed |
| CN-1708514-A | Hydroxyalkyl starch derivatives | FRESENIUS KABI DE GMBH (DE) | 2005-12-14 | — | — | CN | disclosed |
| EP-1599469-A1 | TETRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2005108407-A1 | CYCLOOLEFIN PHOSPHINE LIGANDS AND THEIR USE IN CATALYSIS | DEGUSSA AG (DE) | 2005-11-17 | — | — | WO | disclosed |
| EP-1595888-A1 | Cycloolefin phosphine ligands and their use in catalysis | Degussa AG (DE) | 2005-11-16 | — | — | EP | disclosed |
| EP-1456202-B1 | BENZOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2005-11-09 | — | — | EP | disclosed |
| EP-1592698-A2 | PHOSPHINE COMPOUND, INTERMEDIATE, PALLADIUM-COMPLEX, AND USE THEREOF | Takasago International Corporation (JP) | 2005-11-09 | — | — | EP | disclosed |
| US-6960578-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050234230-A1 | Hydroxyalkyl starch derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2005-10-20 | — | — | US | disclosed |
| US-20050234048-A1 | Glutamate receptor antagonists | ADAM GEO | 2005-10-20 | — | — | US | disclosed |
| WO-2005095385-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-1383501-A4 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1581497-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1372653-A4 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2005-10-05 | — | — | EP | disclosed |
| US-6951886-B2 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1578724-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050209477-A1 | Process for producing vinyl perfluoroalkanesulfonate derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| WO-2005087215-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| CN-1671697-A | Indoles, azaindoles and related heterocyclic 4-alkenyl piperidine amides | BRISTOL MYERS SQUIBB CO (US) | 2005-09-21 | — | — | CN | disclosed |
| EP-1571150-A1 | Process for the preparation of tryptase inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| CN-1662498-A | Novel tetrahydropyridine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2005-08-31 | — | — | CN | disclosed |
| EP-1515724-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1562941-A2 | TRANS-9,10-DEHYDROEPOTHILONE C AND D, ANALOGS THEREOF AND METHOS OF MAKING THE SAME | Kosan Biosciences, Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-08-11 | — | — | US | disclosed |
| WO-2005070407-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| CN-1649870-A | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD (CH) | 2005-08-03 | — | — | CN | disclosed |
| US-6919329-B2 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1553082-A1 | PROCESS FOR PRODUCTION OF VINYL PERFLUOROALKANESULFONATE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005054244-A2 | AZABICYCLOOCTENE AND OTHER TETRAHYDROPYRIDINE DERIVATIVES WITH A NEW SIDE-CHAIN | ACTELION PHARMACEUTICALS LTD (CH) | 2005-06-16 | — | — | WO | disclosed |
| CN-1626534-A | Steroid receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2005-06-15 | — | — | CN | disclosed |
| CN-1205207-C | Substituted indolealkanoic acids | INST FOR PHARMACEUTICAL DESCOV (US) | 2005-06-08 | — | — | CN | disclosed |
| EP-0813868-B1 | Retroviral protease inhibitors | MONSANTO CO (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005044816-A1 | TETRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005040120-A1 | TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005040165-A1 | DIAZABICYCLONONENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005040173-A1 | DIAZABICYCLONONENE AND TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-05-06 | — | — | WO | disclosed |
| EP-1109812-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2005-05-04 | — | — | EP | disclosed |
| EP-1524262-A1 | Inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2005-04-20 | — | — | EP | disclosed |
| US-20050080090-A1 | Naphthalene derivatives | CHENARD BERTRAND L (US) | 2005-04-14 | — | — | US | disclosed |
| CN-1606545-A | Pyrrolidine and piperidine derivates as nk1 antagonists | SCHERING CORP (US) | 2005-04-13 | — | — | CN | disclosed |
| EP-1519920-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2005-04-06 | — | — | EP | disclosed |
| EP-1515724-A1 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| WO-2005009950-A2 | PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-20050009799-A1 | Cyclohexyl derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | US | disclosed |
| WO-2005000842-A1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMAN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| WO-2005000775-A2 | CYCLOHEXYL DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-01-06 | — | — | WO | disclosed |
| US-20050004043-A1 | Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-01-06 | — | — | US | disclosed |
| US-20050004230-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (NOW NAMED PHARMACIA CORPORATION, WHICH IS A WHOLLY OWNED SUBSIDIARY OF PFIZER, INC (US) | 2005-01-06 | — | — | US | disclosed |
| EP-1492772-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS AS ANTITUMOR AGENTS | SCHERING CORPORATION (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20040266821-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | UJJAINWALLA FEROZE | 2004-12-30 | — | — | US | disclosed |
| EP-1487811-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040249219-A1 | Method of making teprenone | BIO-TECHNICAL RESOURCES, A DIVISION OF ARKION LIFE SCIENCES LLC | 2004-12-09 | — | — | US | disclosed |
| WO-2004105738-A2 | USE OF TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004105762-A1 | MEDICAL USE OF DIAZABICYCLONONENE DERIVATIVES AS INHIBITORS OF PARASITE ASPARTIC PROTEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004103367-A1 | BENZOTHIAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES RELATES TO THE ADENOSINE A2A RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-02 | — | — | WO | disclosed |
| US-20040242609-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20040235915-A1 | Benzothiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | US | disclosed |
| US-20040235842-A1 | Carbamic acid esters of benzothiazoles | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | US | disclosed |
| EP-1478629-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-6818658-B2 | TREATING OBESITY, DIABETES, SEXUAL DYSFUNCTION, INCLUDING ERECTILE DYSFUNCTION AND FEMALE SEXUAL DYSFUNCTION. | MERCK & CO., INC. | 2004-11-16 | — | — | US | disclosed |
| WO-2004096769-A1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096799-A1 | TROPANE DERIVATIVES AND THEIR USE AS ACE INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096804-A1 | DIAZABICYCLONONENE AND TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096116-A2 | DIAZABICYCLONONENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096803-A1 | AZABICYCLONONENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
| EP-1299362-A4 | SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2004091488-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| CN-1172917-C | Steroid receptor modulator compounds and methods | ��λ��ҩ��ɷ�����˾ | 2004-10-27 | — | — | CN | disclosed |
| WO-2004089307-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO. INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004087064-A2 | COMPOUNDS AND METHODS FOR USE IN TREATING NEOPLASIA AND CANCER BASED UPON INHIBITORS OF ISOPRENYLCYSTEINE METHYLTRANSFERASE | PURDUE RESEARCH FOUNDATION (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087050-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087159-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| EP-1463716-A1 | PYRROLIDINE AND PIPERIDINE DERIVATES AS NK1 ANTAGONISTS | SCHERING CORPORATION (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040192734-A1 | 4-(3-aminomethylphenyl)piperidin-1-yl]-[5-(2-fluorophenylethynyl)furan-2-yl]-methanone as an inhibitor of mast cell tryptase | AVENTIS PHARMACEUTICALS INC. (US) | 2004-09-30 | — | — | US | disclosed |
| US-20040186132-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2004-09-23 | — | — | US | disclosed |
| WO-2004078717-A1 | ACYLATED PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040176403-A1 | Methods for treating multidrug resistance | JOHNSON WILLIAM W (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1453513-A1 | USE OF FPT INHIBITORS AND AT LEAST TWO ANTINEOPLASTIC AGENTS IN THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2004072088-A2 | PHOSPHINE COMPOUND, INTERMEDIATE, PALLADIUM-COMPLEX, AND USE THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-08-26 | — | — | WO | disclosed |
| EP-1447398-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20040152708-A1 | Trans-9,10-dehydroepothilone C and D, analogs thereof and methods of making the same | KOSAN BIOSCIENCES, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004064774-A2 | DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | disclosed |
| WO-2004060884-A1 | [4-(3-AMINOMETHYLPHENYL) PIPERIDIN-1-YL]- [5-(2-FLUOROPHENYLETHYNYL)FURAN-2-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004058148-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058700-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-6762187-B2 | HETEROCYCLIC NITROGEN COMPOUNDS USED AS ENZYME INHIBITORS FOR PROPHYLAXIS OF HUMAN IMMUNODEFICIENCY VIRUS(HIV) | MONSANTO COMPANY | 2004-07-13 | — | — | US | disclosed |
| US-20040121985-A1 | Novel prenyl transferase inhibitors | GIBBS RICHARD A | 2004-06-24 | — | — | US | disclosed |
| US-20040122018-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION | 2004-06-24 | — | — | US | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040106622-A1 | Aryl-substituted alicylic compound and medical composition comprising the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004043954-A2 | TRANS-9,10-DEHYDROEPOTHILONE C AND D, ANALOGS THEREOF AND METHOS OF MAKING THE SAME | KOSAN BIOSCIENCES INCORPORATED (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-1115687-B1 | 5,6-DIHYDRONAPHTHALENYL DERIVATIVES HAVING RETINOID-LIKE ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20040097546-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2004-05-20 | — | — | US | disclosed |
| US-6734179-B2 | SULFUR COMPOUNDS SUCH AS 4-FLUORO-N-(4-METHOXY-7-(TETRAHYDRO-PYRAN-4-YL)-BENZOTHIAZOL-2-YL) -BENZAMIDE, USED AS PREFERENTIAL ADENOSINE RECEPTOR LIGANDS FOR THE PROPHYLAXIS OF NEURODEGENERATIVE DISORDERS | HOFFMANN-LA ROCHE INC. | 2004-05-11 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1413582-A1 | Dimeric pyrrolobenzodiazepines | Spirogen Limited (GB) | 2004-04-28 | — | — | EP | disclosed |
| US-6727282-B2 | HUMAN IMMUNODEFICIENCY VIRUS (HIV) OR AIDS TREATMENT | G.D. SEARLE & CO. | 2004-04-27 | — | — | US | disclosed |
| EP-0948495-B1 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | AMGEN INC (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6720324-B2 | THERAPY FOR EATING DISORDERS, SEXUAL DISORDERS, PSYCHOLOGICAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-13 | — | — | US | disclosed |
| EP-1398328-A1 | Hydroxyalkyl starch derivatives | Fresenius Kabi Deutschland GmbH (DE) | 2004-03-17 | — | — | EP | disclosed |
| EP-0925301-B1 | HIGHLY LIPOPHILIC CAMPTOTHECIN DERIVATIVES | BIONUMERIK PHARMACEUTICALS INC (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-1224175-B1 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-03-17 | — | — | EP | disclosed |
| US-6703400-B2 | ADMINISTERING BENZO(5,6) CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVE AS ANTITUMOR AGENT; P-GLYCLOPROTEIN INHIBITOR | SCHERING CORPORATION | 2004-03-09 | — | — | US | disclosed |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-04 | — | — | US | disclosed |
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2004-02-26 | — | — | US | disclosed |
| US-6696459-B1 | USING HIGH AFFINITY, HIGH SELECTIVITY QUINOLINE DERIVATIVESW | LIGAND PHARMACEUTICALS INC. | 2004-02-24 | — | — | US | disclosed |
| EP-1383501-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| CN-1471524-A | novel farnesyl protein transferase inhibitors as antitumor agents | ���鹫˾ | 2004-01-28 | — | — | CN | disclosed |
| EP-1382597-A2 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20040006087-A1 | Method of treating cancer using FPT inhibitors and antineoplastic agents | SCHERING CORPORATION | 2004-01-08 | — | — | US | disclosed |
| WO-2004002957-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-01-08 | — | — | WO | disclosed |
| EP-1372653-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20040002542-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-01-01 | — | — | US | disclosed |
| US-20030236247-A1 | N-sulfonylurea apoptosis promoters | ABBVIE INC. | 2003-12-25 | — | — | US | disclosed |
| WO-2003105855-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030232808-A1 | Sulfonyl derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-12-18 | — | — | US | disclosed |
| EP-1371646-A1 | ARYL-SUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION COMPRISING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-12-17 | — | — | EP | disclosed |
| US-20030229099-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | PHARMACOPEIA DRUG DISCOVERY | 2003-12-11 | — | — | US | disclosed |
| US-20030225060-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2003-12-04 | — | — | US | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| US-20030220508-A1 | Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inyhibitors | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | disclosed |
| EP-1007528-B1 | ROBUSTAFLAVONE, INTERMEDIATES AND ANALOGUES AND METHOD FOR PREPARATION THEREOF | ADVANCED LIFE SCIENCES INC (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030216374-A1 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2003-11-20 | — | — | US | disclosed |
| US-20030216422-A1 | Methods for treating multidrug resistance | SCHERING CORPORATION | 2003-11-20 | — | — | US | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
| CN-1454211-A | Nitrogen containing heterobicycles as factor xa inhibitors | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-11-05 | — | — | CN | disclosed |
| US-6638955-B2 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2003-10-28 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030195227-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 2003-10-16 | — | — | US | disclosed |
| WO-2003080586-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2003-10-02 | — | — | WO | disclosed |
| EP-1224174-B1 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2003-09-17 | — | — | EP | disclosed |
| EP-1009755-B1 | STEROID SULFATASE INHIBITORS AND METHODS FOR MAKING AND USING THE SAME | UNIV HOLY GHOST DUQUESNE (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2003072549-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS AS ANTITUMOR AGENTS | SCHERING CORPORATION (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003072553-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
| US-20030158173-A1 | Drugs for treating physiological disorder, respiratory disorders, inflammatory disease, skin disorder, and antidepressants, treating bipolar disorder, drug abuse, drug dependence, gastrointestinal disorder, atherosclerosis | SCHERING CORPORATION | 2003-08-21 | — | — | US | disclosed |
| US-6605630-B1 | Active against drug resistant gram positive pathogens | SYNGENTA LIMITED (GB) | 2003-08-12 | — | — | US | disclosed |
| US-6605634-B2 | Tumor necrosis factor alpha and interleukin-1 (IL-1) mediated diseases; pain, diabetes; cyclooxygenase inhibition | AMGEN, INC. | 2003-08-12 | — | — | US | disclosed |
| US-20030144288-A1 | Benzothiazoles | F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) | 2003-07-31 | — | — | US | disclosed |
| US-6586461-B1 | Geranylgeranyl transferase inhibitors comprising farnesol and geranylgeraniol analogs, used as anticarcinogenic agents and for prevention of restenosis | WAYNE STATE UNIVERSITY | 2003-07-01 | — | — | US | disclosed |
| US-6586430-B1 | Administering azabicyclo compounds to treat human immunodeficiency virus infections and respiratory system disorders | PFIZER INC. | 2003-07-01 | — | — | US | disclosed |
| US-20030120069-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-06-26 | — | — | US | disclosed |
| WO-2003051840-A1 | PYRROLIDINE AND PIPERIDINE DERIVATES AS NK1 ANTAGONISTS | SCHERING CORPORATION (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003047586-A1 | USE OF FPT INHIBITORS AND AT LEAST TWO ANTINEOPLASTIC AGENTS IN THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-1313725-A1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030096819-A1 | Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents | AMGEN INC. | 2003-05-22 | — | — | US | disclosed |
| US-20030092677-A1 | Glutamate receptor antagonists | ADAM GEO (DE) | 2003-05-15 | — | — | US | disclosed |
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-05-01 | — | — | US | disclosed |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-24 | — | — | US | disclosed |
| EP-1181017-B1 | METALLOPROTEASE INHIBITORS | PFIZER LTD (GB) | 2003-04-16 | — | — | EP | disclosed |
| US-20030069261-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-10 | — | — | US | disclosed |
| EP-1299362-A1 | SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF | Synaptic Pharmaceutical Corporation (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-1294660-A2 | METHOD FOR COUPLING ORGANIC COMPOUNDS | MERCK PATENT GmbH (DE) | 2003-03-26 | — | — | EP | disclosed |
| US-6538006-B1 | N-heterocyclic moiety-containing hydroxyethylamine protease inhibitor compounds, methods for making the compounds, and intermediates useful in the method. Also, a method for inhibiting retroviral proteases and for treatment of | PHARMACIA CORPORATION | 2003-03-25 | — | — | US | disclosed |
| US-6531485-B2 | For therapy of bone disorders including osteoporosis | PFIZER INC. | 2003-03-11 | — | — | US | disclosed |
| US-6525042-B1 | Inhibits an activated coagulation factor FXa; anticoagulant, antithrombotic | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-02-25 | — | — | US | disclosed |
| EP-1280764-A2 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2003-02-05 | — | — | EP | disclosed |
| US-6515024-B2 | For therapy of retroviral infection, e.g., an HIV infection | G. D. SEARLE & CO. | 2003-02-04 | — | — | US | disclosed |
| US-6511993-B1 | Substituted alpha-aminosulphonyl-acetohydroxamic acids which are inhibitors of zinc-dependent metalloprotease enzymes | PFIZER INC. | 2003-01-28 | — | — | US | disclosed |
| US-6509328-B1 | Metabotropic glutamate receptor antagonists and accordingly are useful for the treatment of a range of neurological disorders, including psychosis, schizophrenia, Alzheimer's and others | HOFFMANN-LA ROCHE INC. | 2003-01-21 | — | — | US | disclosed |
| US-6506759-B1 | Method for treating HIV-related AIDS comprising administering an effective amount of a composition N-heterocyclic moiety containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in | MONSANTO COMPANY | 2003-01-14 | — | — | US | disclosed |
| US-20030008895-A1 | PROSTAGLANDIN AGONISTS | CAMERON KIMBERLY O (US) | 2003-01-09 | — | — | US | disclosed |
| US-20020198378-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2002-12-26 | — | — | US | disclosed |
| US-20020198216-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | PHARMACOPEIA DRUG DISCOVERY | 2002-12-26 | — | — | US | disclosed |
| US-6489354-B1 | IN PARTICULAR, THESE COMPOUNDS ARE USEFUL AS MODULATORS OF THE CHEMOKINE RECEPTORS CCR-3 AND/OR CCR-5 USEFUL IN THE TREATMENT AND PREVENTION OF ATOPIC CONDITIONS INCLUDING ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, AND ASTHMA | MERCK & CO., INC. | 2002-12-03 | — | — | US | disclosed |
| US-6482851-B1 | Synthesis of dysidiolide and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2002-11-19 | — | — | US | disclosed |
| US-20020165411-A1 | Sterically hindered phosphine ligands and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-11-07 | — | — | US | disclosed |
| EP-1009755-A4 | STEROID SULFATASE INHIBITORS AND METHODS FOR MAKING AND USING THE SAME | UNIV HOLY GHOST DUQUESNE (US) | 2002-11-06 | — | — | EP | disclosed |
| US-6469207-B2 | HIV PROTEASE INHIBITORS; ADMINISTERING TO TREAT AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | G. D. SEARLE & CO. | 2002-10-22 | — | — | US | disclosed |
| EP-1246847-A2 | DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF | Synaptic Pharmaceutical Corporation (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020137942-A1 | Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | VAZQUEZ MICHAEL L (US) | 2002-09-26 | — | — | US | disclosed |
| EP-1242120-A2 | COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE | Pfizer Limited (GB) | 2002-09-25 | — | — | EP | disclosed |
| US-20020133022-A1 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2002-09-19 | — | — | US | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
| CN-1368883-A | Method for lowering serum glucose and triglyceride levels and inhibiting angiogenesis using indolealkanoic acids | INST PHARMACEUTICAL DISCOVERY (US) | 2002-09-11 | — | — | CN | disclosed |
| US-6448405-B1 | COUPLING A 2-HALO-5-NITROBENZOIC ACID AND A 2-METHOXYPHENYL BORONIC ACID; CYCLIZING TO A NITROBENZOCOUMARIN; REDUCING TO THE AMINE; CONVERTING TO A COUMARINO(3,4-F)QUINOLINE; REDUCTION TO A 5H-CHROMENO(3,4-F)QUINOLINE | LIGAND PHARMACEUTICALS INCORPORATED | 2002-09-10 | — | — | US | disclosed |
| WO-2002068387-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002068388-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| US-6440973-B1 | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents | AMGEN INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020115826-A1 | Inhibitors of histone deacetylase | 92229129 QUEBEC INC. (CA) | 2002-08-22 | — | — | US | disclosed |
| US-20020111496-A1 | Inhibitors of glycosyltransferase enzymes | UNIVERSITY OF FLORIDA | 2002-08-15 | — | — | US | disclosed |
| WO-2002062814-A1 | INHIBITORS OF GLYCOSYLTRANSFERASE ENZYMES | THE UNIVERSITY OF FLORIDA (US) | 2002-08-15 | — | — | WO | disclosed |
| CN-1364153-A | Substituted phenoxyacetic acids | INST PHARMACEUTICAL DISCOVERY (US) | 2002-08-14 | — | — | CN | disclosed |
| EP-1224175-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| EP-1224174-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002048160-A1 | STERICALLY HINDERED PHOSPHINE LIGANDS AND USES THEREOF | YALE UNIVERSITY (US) | 2002-06-20 | — | — | WO | disclosed |
| US-6407094-B1 | 4-5-DIDEHYDRO-1,5-BENZODIAZEPIN-2-ONE DERIVATIVES; PSYCHOLOGICAL, NERVOUS SYSTEM, AND BRAIN DISORDERS; COGNITION ACTIVATORS; ALZHEIMER*S DISEASE, SCHIZOPHRENIA | HOFFMANN-LA ROCHE INC. | 2002-06-18 | — | — | US | disclosed |
| EP-1115687-A4 | 5,6-DIHYDRONAPHTHALENYL DERIVATIVES HAVING RETINOID-LIKE ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6399627-B1 | ANTICOAGULANTS; PROTHROMINASE, SERINE PROTEASE INHIBITOR; ACRYLAMIDE DERIVATIVES | COR THERAPEUTICS, INC. | 2002-06-04 | — | — | US | disclosed |
| US-20020058811-A1 | Naphthalene derivatives | CHENARD BERTRAND L (US) | 2002-05-16 | — | — | US | disclosed |
| US-6372764-B1 | ANTIINFLAMMATORY AGENTS AND AIDS TREATMENT | MERCK & CO., INC. | 2002-04-16 | — | — | US | disclosed |
| EP-1193270-A2 | Pyrrolobenzodiazepines | Spirogen Limited (GB) | 2002-04-03 | — | — | EP | disclosed |
| US-6365751-B1 | ACTIVE AGAINST GRAM-POSITIVE BACTERIA, IN PARTICULAR, AGAINST STRAINS RESISTANT TO VANCOMYCIN, AMINOGLYCOSIDES AND PENCILLINS AND DERIVATIVES; NONTOXIC | ZENECA LTD. (GB) | 2002-04-02 | — | — | US | disclosed |
| US-6362201-B1 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | MERCK & CO., INC. | 2002-03-26 | — | — | US | disclosed |
| WO-2002018368-A1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
| EP-1181017-A1 | METALLOPROTEASE INHIBITORS | Pfizer Limited (GB) | 2002-02-27 | — | — | EP | disclosed |
| WO-2002006245-A1 | SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF | SYNAPTIC PHARMARCEUTICAL CORPORATION (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002003981-A1 | METHOD OF MAKING TEPRENONE | DCV, INC. D/B/A BIO-TECHNICAL RESOURCES (US) | 2002-01-17 | — | — | WO | disclosed |
| CN-1331591-A | Piperidines as CCR5 modulators | PFIZER LTD (US) | 2002-01-16 | — | — | CN | disclosed |
| WO-2002002744-A2 | DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-01-10 | — | — | WO | disclosed |
| US-6337398-B1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2002-01-08 | — | — | US | disclosed |
| WO-2002000577-A2 | METHOD FOR COUPLING ORGANIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2002-01-03 | — | — | WO | disclosed |
| EP-1159264-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6319948-B2 | PREVENTION AND/OR MINIMIZATION OF SURGICAL ADHESION FORMATION BY ADMINISTERING CERTAIN SUBSTITUTED (5,6)-DIHYDRONAPHTHALENYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2001-11-20 | — | — | US | disclosed |
| US-6313345-B1 | AIDS TREATMENT | G. D. SEARLE & CO. | 2001-11-06 | — | — | US | disclosed |
| US-6313309-B1 | BENZOTHIOPHENYL-1H-IMIDAZOLE ANALGESICS; HYPOTENSIVE AGENTS, ANTIDEPRESSANTS; SEXUAL, ATTENTION DEFICIT, AND HYPERACTIVE DISORDERS; DELTA-OPIOD RECEPTOR AGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-11-06 | — | — | US | disclosed |
| EP-0811001-B1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER LAMBERT CO (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-1148050-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6303593-B1 | FOR THERAPY HUMAN IMMUNODEFICIENCY VIRUS INFECTION, AQUIRED IMMUNODEFICIENCY SYNDROME (AIDS), INFLAMMATORY AND IMMUNOREGULATORY DISORDER OR DISEASE, ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS | MERCK & CO., INC. | 2001-10-16 | — | — | US | disclosed |
| EP-1140085-A1 | AZABICYCLOALKANES AS CCR5 MODULATORS | Pfizer Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001070675-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2001-09-27 | — | — | WO | disclosed |
| CN-1071327-C | benzothiazine dioxides as endothelin antagonists | WARNER LAMBERT CO (US) | 2001-09-19 | — | — | CN | disclosed |
| EP-1017675-A4 | HIGHLY LIPOPHILIC CAMPTOTHECIN DERIVATIVES | BIONUMERIK PHARMACEUTICALS INC (US) | 2001-08-22 | — | — | EP | disclosed |
| US-6271383-B1 | USEFUL ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS; IN PARTICULAR, AGAINST VARIOUS STRAINS EXHIBITING RESISTANCE TO VANCOMYCIN AND AGAINST E. FAECIUM STRAINS RESISTANT TO BOTH AMINOGLYCOSIDES AND CLINICALLY USED BETA-LACTAMS. | ZENECA LIMITED (GB) | 2001-08-07 | — | — | US | disclosed |
| EP-1115687-A1 | 5,6-DIHYDRONAPHTHALENYL DERIVATIVES HAVING RETINOID-LIKE ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
| WO-2001049690-A1 | 9-AZABICYCLO[4.2.1]NON-2-ENE DERIVATIVES AS LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS | UNIVERSITY OF BRISTOL (GB) | 2001-07-12 | — | — | WO | disclosed |
| EP-1109812-A2 | PYRROLOBENZODIAZEPINES | Spirogen Limited (GB) | 2001-06-27 | — | — | EP | disclosed |
| US-20010004669-A1 | Pyrazinyl-substituted naphthalene derivatives | CHENARD BERTRAND L (US) | 2001-06-21 | — | — | US | disclosed |
| US-20010003780-A1 | Retinoid antagonists and uses thereof | TRAMPOSCH KENNETH M (US) | 2001-06-14 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| EP-0689536-B1 | NAPHTHALENE DERIVATIVES | PFIZER (US) | 2001-05-23 | — | — | EP | disclosed |
| CN-1296485-A | Substituted indolealkanoic acids | INST FOR PHARM DISCOVERY INC (US) | 2001-05-23 | — | — | CN | disclosed |
| EP-1009405-A4 | PYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2001-05-09 | — | — | EP | disclosed |
| EP-1095022-A1 | RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 2001-05-02 | — | — | EP | disclosed |
| US-6225481-B1 | REACTING 6-IODO-5,7,4'-TRIMETHOXYFLAVONE AND 5,7-4'-TRIMETHOXY-3'-(TRIMETHYLSTANNYL)FLAVONE IN PRESENCE OF PALLADIUM COMPOUND AND BASE TO PRODUCE ROBUSTAFLAVONE HEXAMETHYL ETHER, DEMETHYLATING TO PRODUCE ROBUSTAFLAVONE | ADVANCED LIFE SCIENCES, INC. | 2001-05-01 | — | — | US | disclosed |
| WO-2001029011-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001029012-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
| EP-0641325-B1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO CO (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6194601-B1 | USEFUL IN TREATMENT OF SKIN DISORDERS SUCH AS ACNE AND DAMAGE FROM AGE OR IRRADIATION; CHRONIC SKIN INFLAMMATORY INFLAMMATORY DISEASES SUCH AS PSORIASIS AND ATOPIC DERMATITIS; ANTITUMOR AGENTS FOR BREAST CANCER, LUNG CANCER; NONTOXIC | BRISTOL-MYERS SQUIBB COMPANY | 2001-02-27 | — | — | US | disclosed |
| US-6194579-B1 | PROVIDING QUANTITY OF 7-KETO CAMPTOTHECIN; SELECTIVELY SUBSTITUTING LEAVING GROUP AT C7 CARBON OF 7-KETO CAMPTOTHECIN; SELECTIVELY DERIVATIZING C7 CARBON | BIONUMERIK PHARMACEUTICALS, INC. | 2001-02-27 | — | — | US | disclosed |
| US-6180646-B1 | PREVENT REPRODUCTION OF RETROVIRUS | MONSANTO COMPANY | 2001-01-30 | — | — | US | disclosed |
| US-6180643-B1 | ANTAGONIST OF INTERLEUKINS, TUMOR NECROSIS FACTOR | AMGEN INC. | 2001-01-30 | — | — | US | disclosed |
| US-6172205-B1 | DEHALOGENATION, ACID CATALYSIS, CYCLIZATION, RING CONTRACTION; ANTICARCINOGENIC AGENTS | THE TRUSTEES OF COLUMBIA IN THE CITY OF NEW YORK | 2001-01-09 | — | — | US | disclosed |
| US-6169080-B1 | TOPOISOMERASE I INHIBITORS FOR TREATING PATIENTS WITH CANCER | BIONUMERIK PHARMACEUTICALS, INC. | 2001-01-02 | — | — | US | disclosed |
| US-6166037-A | Pyrrolidine and piperidine modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000074681-A1 | METALLOPROTEASE INHIBITORS | PFIZER LIMITED (GB) | 2000-12-14 | — | — | WO | disclosed |
| CN-1274354-A | Robustaflavone, intermediates and analogues and method for prepn. method | MEDICHEM RES INC (US) | 2000-11-22 | — | — | CN | disclosed |
| EP-1043326-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1043325-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1043315-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1041071-A1 | Methods for the preparation of coumarine derivatives | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-1041066-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-0735019-B1 | Retroviral protease inhibitors | MONSANTO CO (US) | 2000-09-20 | — | — | EP | disclosed |
| US-6121450-A | NON-STEROIDAL COMPOUNDS WHICH ARE HIGH AFFINITY, HIGH SELECTIVITY MODULATORS FOR STEROID RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-09-19 | — | — | US | disclosed |
| WO-2000051609-A1 | 3-ALKYL SUBSTITUTED PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000051608-A1 | 3-THIENYL AND 3-FURANYL PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000051607-A1 | 3-CYCLOPROPYL AND 3-CYCLOBUTYL PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000051610-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| US-RE36854-E | FOR TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES, ACNE, ALOPECIA, SKIN AGING, INFLAMMATORY DISEASES AND DISEASES RELATED TO ABNORMAL CELL DIFFERENTIATION OR PROLIFERATION, ADMINISTERING THE VITAMIN D DERIVATIVE OF GIVEN FORMULA | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 2000-09-05 | — | — | US | disclosed |
| EP-1031563-A1 | SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
| US-6107342-A | 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives and a process for the preparation thereof | HOFFMANN-LA ROCHE INC. (US) | 2000-08-22 | — | — | US | disclosed |
| WO-2000047554-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| EP-0701819-B1 | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6093821-A | MAKING 6-(PHENYL OR HETEROARYL)-1,2-DIHYDRO-N-1-PROTECTED QUINOLINE BY REACTING THE CORRESPONDING 6-HALO-DERIVATIVE WITH AN ORGANOBORATE AND ACID TREATMENT TO FORM THE 6-BORO-DERIVATIVE, COUPLING WITH PHENYL OR HETEROARYL HALIDE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-07-25 | — | — | US | disclosed |
| EP-1017675-A1 | HIGHLY LIPOPHILIC CAMPTOTHECIN DERIVATIVES | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2000-07-12 | — | — | EP | disclosed |
| WO-2000038680-A1 | AZABICYCLOALKANES AS CCR5 MODULATORS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
| EP-1009755-A1 | STEROID SULFATASE INHIBITORS AND METHODS FOR MAKING AND USING THE SAME | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2000-06-21 | — | — | EP | disclosed |
| EP-1009405-A1 | PYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2000-06-21 | — | — | EP | disclosed |
| EP-1007528-A2 | ROBUSTAFLAVONE, INTERMEDIATES AND ANALOGUES AND METHOD FOR PREPARATION THEREOF | MEDICHEM RESEARCH, INC. (US) | 2000-06-14 | — | — | EP | disclosed |
| US-6075015-A | Vitamin D compounds and method of preparing these compounds | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 2000-06-13 | — | — | US | disclosed |
| US-6075038-A | Alpha 1a adrenergic receptor antagonists | MERCK & CO., INC. (US) | 2000-06-13 | — | — | US | disclosed |
| EP-1005468-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 2000-06-07 | — | — | EP | disclosed |
| US-6072062-A | Synthesis of C18 -modified vitamin D compounds and compounds resulting therefrom | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 2000-06-06 | — | — | US | disclosed |
| WO-2000017147-A1 | 5,6-DIHYDRONAPHTHALENYL DERIVATIVES HAVING RETINOID-LIKE ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-30 | — | — | WO | disclosed |
| EP-0739204-A4 | PIPERIDINES, PYRROLIDINES AND HEXAHYDRO-1H-AZEPINES PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO INC (US) | 2000-03-15 | — | — | EP | disclosed |
| WO-2000012508-A2 | PYRROLBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| CN-1246856-A | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents | AMGEN INC (US) | 2000-03-08 | — | — | CN | disclosed |
| US-6028078-A | Highly lipophilic camptothecin derivatives | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2000-02-22 | — | — | US | disclosed |
| US-6022994-A | Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G. D. SEARLE &. CO. (US) | 2000-02-08 | — | — | US | disclosed |
| WO-2000002862-A1 | RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-01-20 | — | — | WO | disclosed |
| EP-0970036-A1 | ARYL- AND HETEROARYLCYCLOHEXENYL SUBSTITUTED ALKENES HAVING RETINOID AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY | Allergan Sales, Inc. (US) | 2000-01-12 | — | — | EP | disclosed |
| US-5994544-A | PRODUCING A 5H-CHROMENO(3,4-F)QUINOLINE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0957093-A2 | Retrovial protease inhibitors | MONSANTO COMPANY (US) | 1999-11-17 | — | — | EP | disclosed |
| US-5981528-A | Antibiotic oxazolidinone derivatives | ZENECA LIMITED | 1999-11-09 | — | — | US | disclosed |
| WO-1999051593-A1 | 4-THIONAPHTHYL-1H-IMIDAZOLES WITH ALPHA-2-ADRENERGIC ACTIVITY | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| EP-0948495-A1 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | Amgen Inc., (US) | 1999-10-13 | — | — | EP | disclosed |
| US-5965565-A | PIPERIDINES, PYRROLIDINES, AND HEXAHYDRO-1H-AZEPINES OF GIVEN FORMULA; CAN BE USED TO PROMOTE GROWTH OF LIVESTOCK AND IN HUMANS TREAT PHYSIOLOGICAL OR MEDICAL CONDITIONS CHARACTERIZED BY GRWOTH HORMONE DEFIENCY | MERCK & CO., INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5948790-A | VIRICIDES | MOSANTO COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| WO-1999040079-A1 | SYNTHESIS OF DYSIDIOLIDE AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1999-08-12 | — | — | WO | disclosed |
| US-5932743-A | Methods for the solid phase synthesis of substituted indole compounds | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-08-03 | — | — | US | disclosed |
| US-5922722-A | PIPERIDINE OR PIPERAZINE DERIVATIVES TO TREAT BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. (US) | 1999-07-13 | — | — | US | disclosed |
| EP-0925301-A1 | HIGHLY LIPOPHILIC CAMPTOTHECIN DERIVATIVES | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1999029704-A1 | A SYNTHETIC PROCESS TOWARD TOTAL SYNTHESIS OF ELEUTHERUBIN AND ITS ANALOGUES AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1999-06-17 | — | — | WO | disclosed |
| US-5910491-A | Highly lipophilic camptothecin derivatives | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-06-08 | — | — | US | disclosed |
| US-5880115-A | Steroid sulfatase inhibitors and methods for making and using the same | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 1999-03-09 | — | — | US | disclosed |
| WO-1999010292-A2 | ROBUSTAFLAVONE, INTERMEDIATES AND ANALOGUES AND METHOD FOR PREPARATION THEREOF | MEDICHEM RESEARCH, INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999010342-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999009984-A1 | PYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999009007-A1 | SOLID PHASE SYNTHESIS OF 2,3-DISUBSTITUTED INDOLE COMPOUNDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-02-25 | — | — | WO | disclosed |
| EP-0721461-B1 | SYNTHESIS OF 17-(3-PYRIDYL) STEROIDS | BTG INT LTD (GB) | 1999-02-03 | — | — | EP | disclosed |
| WO-1999003876-A1 | STEROID SULFATASE INHIBITORS AND METHODS FOR MAKING AND USING THE SAME | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 1999-01-28 | — | — | WO | disclosed |
| EP-0882042-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | AstraZeneca UK Limited (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998046228-A1 | RETINOID ANTAGONISTS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| EP-0831823-A4 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1998-10-21 | — | — | EP | disclosed |
| EP-0865280-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-09-23 | — | — | EP | disclosed |
| WO-1998039284-A1 | ARYL- AND HETEROARYLCYCLOHEXENYL SUBSTITUTED ALKENES HAVING RETINOID AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
| US-5804578-A | USEFUL FOR TREATING OSTEOPROSIS, CATABOLIC ILLNESS, IMMUNE DEFICIENCY, BONE FRACTURE, SHROT STATURE IN CHILDREN, OBASITY, SLEEP DISORDER, CACHEXIA AND PROTEIN LOSS DUE TO CHRONIC ILLNESS SUCH AS AIDS AND CANCER | MERCK & CO., INC. (US) | 1998-09-08 | — | — | US | disclosed |
| EP-0558603-B1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO CO (US) | 1998-08-26 | — | — | EP | disclosed |
| WO-1998022457-A9 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998035940-A1 | HIGHLY LIPOPHILIC CAMPTOTHECIN DERIVATIVES | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1998-08-20 | — | — | WO | disclosed |
| WO-1998025897-A1 | PIPERIDINES, PYRROLIDINES AND HEXAHYDRO-1H-AZEPINES PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5760076-A | Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D SEARLE & CO. (US) | 1998-06-02 | — | — | US | disclosed |
| US-5760276-A | TREATING SKIN DISORDERS, REDUCING SIDE EFFECTS OF RETINOIDS | ALLERGAN (US) | 1998-06-02 | — | — | US | disclosed |
| WO-1998022457-A1 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | AMGEN INC. (US) | 1998-05-28 | — | — | WO | disclosed |
| US-5756534-A | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 1998-05-26 | — | — | US | disclosed |
| CN-1180351-A | Benzothiazine dioxides as endothelin antagonists | WARNER LAMBERT CO (US) | 1998-04-29 | — | — | CN | disclosed |
| EP-0558630-B1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO CO (US) | 1998-04-08 | — | — | EP | disclosed |
| EP-0831823-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5731317-A | Bridged piperidines promote release of growth hormone | MERCK & CO., INC. (US) | 1998-03-24 | — | — | US | disclosed |
| CN-1175247-A | Steroid receptor modulator compounds and methods | LIGAND PHARM INC (US) | 1998-03-04 | — | — | CN | disclosed |
| WO-1998007727-A1 | HIGHLY LIPOPHILIC CAMPTOTHECIN DERIVATIVES | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1998-02-26 | — | — | WO | disclosed |
| US-5721251-A | INCREASING SECRETION OF GROWTH HORMONE IN HUMANS AND ANIMALS | MERCK & CO., INC. (US) | 1998-02-24 | — | — | US | disclosed |
| US-5719104-A | WEED CONTROL IN CROPS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-02-17 | — | — | US | disclosed |
| US-5714605-A | HIV PROTEASE INHIBITOR | MONSANTO COMPANY (US) | 1998-02-03 | — | — | US | disclosed |
| US-5708004-A | ENZYME INHIBITORS FOR TREATMENT OF AIDS | MONSANTO COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0815856-A2 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
| US-5703076-A | TREATING HIV, AIDS | G. D. SEARLE & CO. (US) | 1997-12-30 | — | — | US | disclosed |
| EP-0813867-A2 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 1997-12-29 | — | — | EP | disclosed |
| EP-0813868-A2 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5698569-A | Retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1997-12-16 | — | — | US | disclosed |
| EP-0811001-A1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-12-10 | — | — | EP | disclosed |
| US-5696127-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5696133-A | ADMINISTERING COMPOUND WHICH MODULATES ACTIVITY OF PROGESTERONE RECEPTOR | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5696130-A | Tricyclic steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5693809-A | PREGNANES FOR TREATING ALOPECIA, ACNE AND SKIN DISORDER | MERCK & CO., INC. (US) | 1997-12-02 | — | — | US | disclosed |
| US-5693647-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5693646-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5688808-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| US-5688810-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0801653-A3 | — | SANDOZ LTD | 1997-10-29 | — | — | EP | disclosed |
| EP-0801653-A2 | TETRACYCLIC TRITERPENES | SANDOZ LTD. (CH) | 1997-10-22 | — | — | EP | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1997036873-A1 | PIPERIDINES, PYRROLIDINES AND HEXAHYDRO-1H-AZEPINES PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997030995-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-28 | — | — | WO | disclosed |
| US-5648364-A | HETEROCYCLIC PEPTIDE COMPOUNDS AS ENZYME INHIBITORS | MONSANTO COMPANY (US) | 1997-07-15 | — | — | US | disclosed |
| CN-1154113-A | Tetracyclic triterpenes | SANDOZ LTD (CH) | 1997-07-09 | — | — | CN | disclosed |
| US-5643924-A | Retroviral protease inhibitors | MONSANTO COMPANY OF ST. LOUIS (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0656886-B1 | N-(ALKANOYLAMINO-2-HYDROXYPROPYL)-SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1997-06-25 | — | — | EP | disclosed |
| US-5637742-A | Vitamin D compound, method of preparing this compound and intermediate therefor | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1997-06-10 | — | — | US | disclosed |
| WO-1997017967-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-05-22 | — | — | WO | disclosed |
| EP-0738251-A4 | PALLADIUM CATALYZED ALKYLATIVE CYCLIZATION USEFUL IN SYNTHESES OF VITAMIN D AND ANALOGUES | UNIV LELAND STANFORD JUNIOR (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5622949-A | AIDS THERAPY | G. D. SEARLE & CO. (US) | 1997-04-22 | — | — | US | disclosed |
| US-5620977-A | HUMAN IMMUNODEFICIENCY VIRUS | G.D. SEARLE & CO. (US) | 1997-04-15 | — | — | US | disclosed |
| US-5618807-A | Method for preparing 17-substituted steroids useful in cancer treatment | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1997-04-08 | — | — | US | disclosed |
| EP-0765310-A1 | HERBICIDAL BICYCLIC AND TRICYCLIC IMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-04-02 | — | — | EP | disclosed |
| US-5610190-A | Retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1997-03-11 | — | — | US | disclosed |
| EP-0514942-B1 | Novel benzopyran derivatives and processes for the preparation thereof | KOREA RES INST CHEM TECH (KR) | 1997-03-05 | — | — | EP | disclosed |
| US-5604213-A | STEROID DEPENDENT CANCERS SUCH AS PROSTATE AND BREAST CANCER | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1997-02-18 | — | — | US | disclosed |
| US-5602175-A | HYDROXYETHYLAMINE COMPOUNDS; USEFUL IN TREATMENT OF INFECTIONS CAUSED BY THE HUMAN IMMUNODEFICIENCY VIRUS | G.D. SEARLE & CO. (US) | 1997-02-11 | — | — | US | disclosed |
| US-5602119-A | TREATMENT OF HIV AND AIDS | G. D. SEARLE & CO. | 1997-02-11 | — | — | US | disclosed |
| US-5599811-A | PHENYL OR DIOXYPHENYL SUBSTITUENTS; DRUGS | WARNER-LAMBERT COMPANY (US) | 1997-02-04 | — | — | US | disclosed |
| US-5597826-A | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1997-01-28 | — | — | US | disclosed |
| EP-0666841-B1 | SUCCINOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1996040135-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0739204-A1 | PIPERIDINES, PYRROLIDINES AND HEXAHYDRO-1H-AZEPINES PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO. INC. (US) | 1996-10-30 | — | — | EP | disclosed |
| EP-0738251-A1 | PALLADIUM CATALYZED ALKYLATIVE CYCLIZATION USEFUL IN SYNTHESES OF VITAMIN D AND ANALOGUES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1996-10-23 | — | — | EP | disclosed |
| EP-0735019-A2 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 1996-10-02 | — | — | EP | disclosed |
| EP-0521550-B1 | Vitamin D compound, method of preparing this compound and intermediate therefor | DUPHAR INT RES (NL) | 1996-09-18 | — | — | EP | disclosed |
| EP-0731088-A2 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0633245-B1 | Vitamin D compounds and method of preparing these compounds | DUPHAR INT RES (NL) | 1996-09-04 | — | — | EP | disclosed |
| WO-1996026195-A1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-08-29 | — | — | WO | disclosed |
| EP-0721461-A1 | SYNTHESIS OF 17-(3-PYRIDYL) STEROIDS | BTG INTERNATIONAL LIMITED (GB) | 1996-07-17 | — | — | EP | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
| US-5510349-A | HUMAN IMMUNODEFICIENCY VIRUS | G.D. SEARLE & CO. (US) | 1996-04-23 | — | — | US | disclosed |
| US-5510378-A | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1996-04-23 | — | — | US | disclosed |
| US-5510487-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1996-04-23 | — | — | US | disclosed |
| EP-0558673-B1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO CO (US) | 1996-04-17 | — | — | EP | disclosed |
| EP-0701819-A2 | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1996-03-20 | — | — | EP | disclosed |
| US-5493029-A | USEFUL IN TREATING ASTHMA AND HYPERTENSION | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1996-02-20 | — | — | US | disclosed |
| US-5492920-A | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone | MERCK & CO., INC. (US) | 1996-02-20 | — | — | US | disclosed |
| WO-1996003419-A1 | TETRACYCLIC TRITERPENES | SANDOZ LTD. (CH) | 1996-02-08 | — | — | WO | disclosed |
| EP-0682654-A4 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE. | MERCK & CO INC (US) | 1996-01-17 | — | — | EP | disclosed |
| US-5482947-A | ENZYME INHIBITORS FOR HIV PROTEASE INHIBITION FROM UREA OR THIOUREA COMPOUNDS | TALLEY JOHN J (US) | 1996-01-09 | — | — | US | disclosed |
| EP-0689536-A1 | NAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1996-01-03 | — | — | EP | disclosed |
| US-5475013-A | Inhibit human immunodeficiency virus protease | MONSANTO COMPANY (US) | 1995-12-12 | — | — | US | disclosed |
| EP-0682654-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO. INC. (US) | 1995-11-22 | — | — | EP | disclosed |
| US-5463104-A | Treating human immunodeficiency virus infection | G. D. SEARLE & CO. (US) | 1995-10-31 | — | — | US | disclosed |
| WO-1995027698-A1 | HERBICIDAL BICYCLIC AND TRICYCLIC IMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-10-19 | — | — | WO | disclosed |
| US-5449668-A | Administering to treat skin or immune diseases; cosmetics, antiinflammatory agents | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1995-09-12 | — | — | US | disclosed |
| US-5446225-A | Reacting halide or pseudohalide with 1,6 or 1,7 enyne in presence of palladium catalyst | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV. (US) | 1995-08-29 | — | — | US | disclosed |
| EP-0660835-A4 | PROCESS FOR PREPARING CERTAIN PYRROLO 3,4- -I(B))QUINOLINES, CERTAIN 1H-PYRANO 3',4':6,7)INDOLIZINO 1,2--I(B))QUINOLIN-3,14(4H,12H)-DIONES, AND CERTAIN 8-METHYL-7-(OXOPROPYL)-INDOLIZINO 1,2--I(B))QUINOLIN-9(11H)-ONES. | — | 1995-08-16 | — | — | EP | disclosed |
| EP-0666841-A1 | SUCCINOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS. | SEARLE & CO (US) | 1995-08-16 | — | — | EP | disclosed |
| EP-0660835-A1 | PROCESS FOR PREPARING CERTAIN PYRROLO 3,4- $i(b)]QUINOLINES, CERTAIN 1H-PYRANO 3',4':6,7]INDOLIZINO 1,2-$i(b)]QUINOLIN-3,14(4H,12H)-DIONES, AND CERTAIN 8-METHYL-7-(OXOPROPYL)-INDOLIZINO 1,2-$i(b)]QUINOLIN-9(11H)-ONES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-07-05 | — | — | EP | disclosed |
| WO-1995017363-A1 | PALLADIUM CATALYZED ALKYLATIVE CYCLIZATION USEFUL IN SYNTHESES OF VITAMIN D AND ANALOGUES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1995-06-29 | — | — | WO | disclosed |
| EP-0656886-A1 | N-(ALKANOYLAMINO-2-HYDROXYPROPYL)-SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS. | SEARLE & CO (US) | 1995-06-14 | — | — | EP | disclosed |
| WO-1995013069-A1 | PIPERIDINES, PYRROLIDINES AND HEXAHYDRO-1H-AZEPINES PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1995-05-18 | — | — | WO | disclosed |
| WO-1995009178-A1 | SYNTHESIS OF 17-(3-PYRIDYL) STEROIDS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-04-06 | — | — | WO | disclosed |
| US-5403940-A | Vitamin D compound, method of preparing this compound and intermediate thereof | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1995-04-04 | — | — | US | disclosed |
| EP-0641325-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| EP-0633245-A1 | Vitamin D compounds and method of preparing these compounds | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1995-01-11 | — | — | EP | disclosed |
| CN-1096297-A | The method of synthetic camptothecine and Mai Pi star and their analogue and allied compound | SMITHKLINE BEECHAM CORP (US) | 1994-12-14 | — | — | CN | disclosed |
| WO-1994021619-A1 | NAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| WO-1994018169-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| WO-1994010133-A1 | SUCCINOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-05-11 | — | — | WO | disclosed |
| US-5300511-A | Spiro-benzopyran derivatives and useful for treating asthma and hypertension | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1994-04-05 | — | — | US | disclosed |
| WO-1994005672-A1 | PROCESS FOR PREPARING CERTAIN PYRROLO[3,4- b]QUINOLINES, CERTAIN 1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLIN-3,14(4H,12H)-DIONES, AND CERTAIN 8-METHYL-7-(OXOPROPYL)-INDOLIZINO[1,2-b]QUINOLIN-9(11H)-ONES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-03-17 | — | — | WO | disclosed |
| WO-1994004491-A1 | N-(ALKANOYLAMINO-2-HYDROXYPROPYL)-SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-03-03 | — | — | WO | disclosed |
| US-5284841-A | Benzo-fused lactams promote release of growth hormone | MERCK & CO., INC. (US) | 1994-02-08 | — | — | US | disclosed |
| WO-1993023379-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993023368-A1 | UREA-CONTAINING HYDROXYETHYLAMINE COMPOUNDS AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993023039-A1 | SUBSTITUTED 4-AZA-5A-ANDROSTAN-ONES AS 5A-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| EP-0558630-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558603-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558673-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558657-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0554400-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-08-11 | — | — | EP | disclosed |
| EP-0521550-A2 | Vitamin D compound, method of preparing this compound and intermediate therefor | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1993-01-07 | — | — | EP | disclosed |
| EP-0514942-A1 | Novel benzopyran derivatives and processes for the preparation thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1992-11-25 | — | — | EP | disclosed |
| WO-1992008701-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008688-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008699-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008698-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| US-5075327-A | Antipsoriatic agents | HOFFMANN-LA ROCHE INC. (US) | 1991-12-24 | — | — | US | disclosed |
| CN-1045972-A | 5-replaces-1,4-dihydro-4-oxo-naphthyridine-3-carboxylic acid (ester) antimicrobial drug | BRISTOL MYERS SQUIBB CO (US) | 1990-10-10 | — | — | CN | disclosed |
| CN-1045972-A | 5-replaces-1,4-dihydro-4-oxo-naphthyridine-3-carboxylic acid (ester) antimicrobial drug | BRISTOL MYERS SQUIBB CO (US) | 1990-10-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | CA1 2356/4885CA2 1899/4885CA7 2734/4885 |
| US-10150109-B2 | Palladium(II)-silica supported catalyst | PDK2, SIK2, SIK1 | CA1 1516/4885CA2 1223/4885CA7 334/4885 |
| US-11253525-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | CA1 2325/4885CA2 1808/4885CA7 2716/4885 |
| US-20070072924-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | SQLE, ACE, AGTR2 | CA1 2640/4885CA2 754/4885CA7 899/4885 |
| US-20170283434-A1 | NK1 ANTAGONISTS | HRH4, CRHR2, HRH2 | CA1 2926/4885CA2 2999/4885CA7 4430/4885 |
| US-11542238-B2 | Pyrimidine cyclohexenyl glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | CA1 4712/4885CA2 4360/4885CA7 4642/4885 |
| US-20060189623-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | CA1 264/4885CA2 562/4885CA7 1047/4885 |
| US-11242319-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | CA1 1848/4885CA2 2550/4885CA7 3479/4885 |
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | DNPEP, ASPH, PEPD | CA1 826/4885CA2 1361/4885CA7 1583/4885 |
| US-20140030221-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | CA1 4036/4885CA2 4276/4885CA7 2936/4885 |
| US-10662171-B2 | Antidiabetic bicyclic compounds | GPR119, GPR65, GLP1R | CA1 4687/4885CA2 2230/4885CA7 4267/4885 |
| US-20050209477-A1 | Process for producing vinyl perfluoroalkanesulfonate derivative | PFAS, FGFR1, F7 | CA1 1253/4885CA2 539/4885CA7 45/4885 |
| US-20080146572-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | BAX, BCL2, BAD | CA1 3001/4885CA2 2921/4885CA7 3784/4885 |
| US-20250250244-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | HTR2C, DRD2, HTR2A | CA1 4371/4885CA2 4539/4885CA7 4828/4885 |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | CA1 3943/4885CA2 3285/4885CA7 2644/4885 |
| US-20090131419-A1 | Sulphones which modulate the action of gamma secretase | BACE1, BACE2, PSEN1 | CA1 435/4885CA2 3182/4885CA7 4417/4885 |
| US-20140148412-A1 | NOVEL 17B-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS | GABRB1, GABRB3, GABRB2 | CA1 2352/4885CA2 2587/4885CA7 3199/4885 |
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | CA1 4832/4885CA2 4712/4885CA7 4484/4885 |
| US-20170275318-A1 | SOLID-SUPPORTED PALLADIUM (II) COMPLEX AS A HETEROGENEOUS CATALYST FOR CROSS COUPLING REACTIONS AND METHODS THEREOF | SIK1, SIK2, ULK2 | CA1 2983/4885CA2 3492/4885CA7 2467/4885 |
| US-20140171410-A1 | Batrachotoxin Analogues, Compositions, Uses, and Preparation Thereof | TRPV1, TRPV4, TRPV5 | CA1 935/4885CA2 191/4885CA7 421/4885 |
| US-20080103311-A1 | Retroviral protease inhibitors | PREP, DNPEP, SERPINB1 | CA1 2123/4885CA2 4309/4885CA7 3490/4885 |
| US-20190276438-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORC, RORA | CA1 1722/4885CA2 2133/4885CA7 2204/4885 |
| US-20060293364-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | HCAR1, HCAR2, FFAR1 | CA1 3956/4885CA2 2751/4885CA7 3530/4885 |
| US-20150111921-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEROF | TEK, CTTN, FLT1 | CA1 2055/4885CA2 1550/4885CA7 1058/4885 |
| US-20060052611-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIFC1 | CA1 3711/4885CA2 3418/4885CA7 4012/4885 |
| US-20110015184-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR10, CXCL10, CXCR3 | CA1 1342/4885CA2 628/4885CA7 266/4885 |
| US-20210186963-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, NR0B1, NCOA3 | CA1 2905/4885CA2 1481/4885CA7 1980/4885 |
| US-20030216422-A1 | Methods for treating multidrug resistance | ABCC1, ABCB1, SLC11A2 | CA1 1526/4885CA2 523/4885CA7 1014/4885 |
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ESR2, ERLIN1, ESRRG | CA1 2723/4885CA2 4093/4885CA7 4119/4885 |
| US-20030092677-A1 | Glutamate receptor antagonists | GRM1, GRM3, GRM2 | CA1 951/4885CA2 1423/4885CA7 3848/4885 |
| US-12048710-B2 | Compositions and methods for modification of biomolecules | PTMS, QPCT, ANPEP | CA1 812/4885CA2 1047/4885CA7 1300/4885 |
| US-20190161458-A1 | ARYL HALIDE CROSS-COUPLING METHOD AND PRODUCT MADE THEREFROM | ITK, SHPRH, SYMPK | CA1 4318/4885CA2 3971/4885CA7 3032/4885 |
| US-20250214930-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | CA1 1756/4885CA2 813/4885CA7 1767/4885 |
| US-20070004803-A1 | Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase | BHMT, BHMT2, GNMT | CA1 3783/4885CA2 3490/4885CA7 3718/4885 |
| US-20060020009-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | HAT1, UBXN4, PRSS1 | CA1 3183/4885CA2 4253/4885CA7 2365/4885 |
| US-20170190737-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | CA1 4036/4885CA2 4276/4885CA7 2936/4885 |
| US-20130225825-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | CMA1, TPSAB1, TPSB2 | CA1 795/4885CA2 463/4885CA7 516/4885 |
| US-10106546-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | CA1 1848/4885CA2 2550/4885CA7 3479/4885 |
| US-20010004669-A1 | Pyrazinyl-substituted naphthalene derivatives | HTR4, HCRTR2, CNR2 | CA1 2946/4885CA2 1407/4885CA7 1705/4885 |
| US-20190022093-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, NR0B1, NCOA3 | CA1 3196/4885CA2 1576/4885CA7 2040/4885 |
| US-20210024546-A1 | OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS | PYM1, MAG, MAGI3 | CA1 3975/4885CA2 3822/4885CA7 4151/4885 |
| US-20150105376-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, PNLIP, LPL | CA1 3875/4885CA2 1815/4885CA7 1765/4885 |
| US-20240254079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | CA1 1756/4885CA2 813/4885CA7 1767/4885 |
| US-20080306264-A1 | bidentante optionally N-containing P-ligands embracing a two-ring-system; for transition metal complexes to be used as catalysts | CCNE2, NDUFS2, SOD1 | CA1 3211/4885CA2 2196/4885CA7 2434/4885 |
| US-10632196-B2 | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | GABRA5, BCR, GABRA4 | CA1 1406/4885CA2 4054/4885CA7 1889/4885 |
| US-10377723-B2 | Solid-supported catalyst for cross-coupling | SIK1, SIK2, SGK1 | CA1 2549/4885CA2 3208/4885CA7 2400/4885 |
| US-20160340279-A1 | SUBSTITUTED (4'-HYDROXYPHENYL)CYCLOAKLKANE COMPOUNDS AND USES THEREOF AS SELECTIVE AGONISTS OF THE ESTROGEN RECEPTOR BETA ISOFORM | ESR2, GPER1, ESRRG | CA1 4391/4885CA2 4030/4885CA7 4502/4885 |
| US-20170210701-A1 | SUBSTITUTED CYANO CYCLOALKYL PENTA-2,4-DIENES, CYANO CYCLOALKYL PENT-2-EN-4-YNES, CYANO HETEROCYCLYL PENTA-2,4-DIENES AND CYANO HETEROCYCLYL PENT-2-EN-4-YNES AS ACTIVE SUBSTANCES | CBR3, NPY2R, CBR1 | CA1 2015/4885CA2 781/4885CA7 2177/4885 |
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | CA1 3956/4885CA2 2751/4885CA7 3530/4885 |
| US-20150274774-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | CA1 4036/4885CA2 4276/4885CA7 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.